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 ABSTRACT
 
 The occurrence of atypical kinetics in cytochrome P450 reactions can confound in 
vitro determinations of a drug's kinetic parameters. During drug development, inaccurate 
kinetic parameter estimates can lead to incorrect decisions about a lead compound's 
potential for success. It has become widely accepted that in certain CYP subfamilies 
more than one molecule can occupy the active site simultaneously, in some cases 
resulting in enhanced substrate turnover (heteroactivation). However, the specific 
mechanism(s) by which dual-compound binding results in heteroactivation remain 
unclear. It is known that orientation of the substrate in the active site, as dictated by 
interactions with active site residues, plays a large role in metabolic outcome. Effector 
compounds have  been shown in vitro to alter substrate position in the active site. Here, 
data obtained via in silico methods including docking, molecular dynamics, semi-
empirical and ab initio quantum mechanics indicate that direct interaction between 
effector and substrate can play a role in stabilizing the substrate in an alternative 
conformation conducive to oxidation. In this study a high-throughput screening computer 
model of heteroactivation of flurbiprofen metabolism by CYP2C9 has been developed for 
the purpose of elucidating key interactions between substrate, effector, and enzyme 
responsible for heteroactivation in this system, as well as to predict as yet unknown 
activators. 
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CHAPTER I 
Background 
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1.1. Overview of P450 Structure and Function 
 
1.1.1. Introduction 
 Cytochrome P450 enzymes are responsible for the metabolism of about 90% of 
xenobiotics 1, including pollutants, toxins, and therapeutic compounds, as well as 
certain endogenous compounds such as steroids 2. These enzymes are membrane-
bound, and are principally found in the endoplasmic reticulum of hepatocytes, though 
they can also be found in considerable quantities in cells of other tissues, including the 
lungs, brain, and small intestine. Nearly all P450 enzymes are monoxygenases-- they 
transfer a single oxygen to the substrate compound using the reaction scheme described 
below (Figure 1.1), however the CYP superfamily can be divided into various families 
and subfamilies whose metabolic function is unique to specific physicochemical classes 
of substrates.  
 In the presence of substrate three types of binding mechanisms are known to 
occur, depending on the chemical composition of the substrate as well as the CYP 
isozyme involved in catalysis. These are Type I, Type II, and Reverse Type I. These 
mechanisms are defined by their respective UV spectra (Figure 1.2). 
  In a typical Type I interaction substrate enters the active site and in doing so 
displaces the bound water molecule, destabilizing the low-spin state and causing the low-
spin-high-spin equilibrium to shift toward the high-spin state. With its 3d electrons now  
 3 
 
Figure 1.1. CYP Catalytic Reaction Cycle. 
The CYP catalytic reaction cycle is illustrated. Adapted from Guengerich3. 
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Figure 1.2. Type I and Type II Binding Spectra.  
Type I and Type II binding spectra are shown. From Jefcoate et al 4. 
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unpaired and redistributed, the ionic radius of the iron increases, rendering it too large to 
fit inside the porphyrin ring without distorting its geometry. Therefore the heme group 
"flutes" such that the iron atom pulls proximally out of the porphyrin plane (Figure 1.3). 
It is at this point that the substrate binds to the heme iron. It is generally believed that 
substrate binding elicits a conformational change in the enzyme that increases the binding 
affinity of electron-donating reductase. NADPH-cytrochrome P450 reductase (CPR)is the 
obligatory redox transfer protein for providing the first electron of this two-electron 
process. However, the second electron may be provided by either CPR or cytochrome b5. 
Electron transfer from the reductase to the heme iron changes its oxidation state from +3 
to +2. Diatomic oxygen that diffuses into the active site can now bind to the ferrous iron. 
In the step that follows, CPR or b5 donates a second redox equivalent to the heme, and so 
creates a superoxide, which subsequently accepts a proton from either the side-chain 
hydroxyl group of a conserved threonine, or from a water molecule bound to that residue, 
heterolytically cleaving the dioxygen bond. The resulting structure collapses into excess 
water and what is speculated to be a highly reactive oxyferryl species in which iron exists 
in the +4 oxidation state. In an as-yet speculative reaction likely involving hydrogen 
extraction 3, this oxygen is transferred to the substrate site of metabolism, simultaneously 
returning the heme iron to its resting 3+ state and releasing oxidized metabolite from the 
catalytic site. 
 In Type II binding the inhibitor displaces water as the sixth ligand and stabilizes 
iron in a ferric state, which  
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Figure 1.3. Heme Geometries of High-Spin and Low-Spin States. 
Spin states Type I (A) and Type II (B) are illustrated. CYX is the cysteine residue 
connecting the heme iron to the apoprotein. 
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is not conducive to metabolism. Suicide inhibition does not produce a metabolite and 
renders the enzyme permanently inactivated. However, in certain cases such as 
diclofenac metabolism by CYP2C9, exhibit a Type II UV spectrum in vitro, yet are in 
fact metabolized and do not adversely affect the enzyme's metabolic ability 5. The 
mechanism(s) responsible for this phenomenon is/are as yet unknown. Reverse Type I 
binding occurs with ligands possessing functional groups that coordinate weakly to the 
heme, and is thought to occur via a mechanism involving stabilizing the apoprotein 
conformation such that the ferric heme geometry is favored. It is thought to result at times 
from allosteric substrate binding 4. 
 
1.1.2. General structural characteristics of CYPs 
 The overall secondary structure is conserved among all human P450s, and 
consists of a "core region" of helices D, E, I, J, K, L and the heme, which is sandwiched 
between helices L and I (Figure 1.4). A cysteine residue links the heme moiety with the 
apoprotein by coordinating with the heme iron. Also highly conserved is a threonine 
(Thr-301) located in the I helix in the interior of the protein, thought to be involved in the 
transfer of protons in oxidative reactions with substrates. The iron-ligated cysteine is 
flanked by several residues in the sequence RXCXG, which is highly conserved also. 
 
1.1.3. Overview of behavior and structural characteristics of CYP2C9 
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Figure 1.4. Tertiary Structure of CYP2C9 Highlighting Conserved Core Region. 
The tertiary structure of CYP2C9 is illustrated and general secondary structures conserved 
among human CYPs are labeled. The heme is shown in stick-form colored crimson. 
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 Of all CYPs involved in drug metabolism, CYP2C9 is one isozyme deserving 
closer study. CYP2C9-mediated oxidation occurs with nearly one-fifth of all currently 
marketed drugs 6, making mechanistic understanding of the enzyme's metabolic process 
of prime importance to drug development and design.  
 Substrates of CYP2C9 tend to be small, aromatic, weakly acidic compounds, such  
as phenytoin, ibuprofen, naproxen, tolbutamide, fluoxetine, and warfarin. The acidic 
group is typically about 7 Ångstroms from the site of oxidation 7. Occasionally, however, 
CYP2C9 metabolizes compounds that are neutral, such as benzo[a]pyrene, and some 
aliphatic compounds 8.  
 2C9 exhibits polymorphism in some individuals, with different allelic variants 
occurring in different ethnic populations. These differ from the wild-type by a single 
residue; the most common being R144C (*2), I359L (*3), and D360E (*5). All are slow 
metabolizers compared to the wild-type. The *2 variant occurs in about 20% of 
Caucasians, 9% in people of African descent, and less than 1% in Asians. 9. CYP2C9*3 
is present in about 12% of Caucasians, < 2% in people of African descent, and 4% of 
Asians. The *5 phenotype is found only in people of African descent, and is very rare, 
occurring in less than 1% of the population 10. Due to the metabolic inefficiency of these 
polymorphic variants, drugs with narrow therapeutic indices will require an adjustment in 
dosage for patients with a non-wild-type CYP2C9 phenotype. Otherwise, toxicity or lack 
of therapeutic effect may result, depending on the drug being administered. 
 Structurally, CYP2C9 shares over 80% amino acid sequence identity to other 2C 
enzymes 11. However, important residues form structural elements that create an active 
site topology unique to CYP2C9. Publication of the x-ray crystal structure (Protein 
 10 
Databank Code 1R9O) by Wester in 2004 elucidated the roles of several key residues. it 
was observed that conserved residue Arg-108, which has been shown to be important in 
the oxidative functionality of the enzyme toward acidic substrates flurbiprofen, S-
warfarin, and diclofenac 5, forms hydrogen bonds with I-helix residues Asp-293 and Asn-
289. Arg-108 lies in a thirteen-residue segment in the BC-loop sandwiched between two 
glycine residues whose proton side chains render the region highly flexible. Residues 293 
and 289 may aid in stabilizing Arg-108 such that its amino side chain faces the active site 
interior 12. Asp-293 may also form hydrogen bonds with the backbone of a segment of the 
BC-loop composed of residues 111 through 114. In this segment Val-113 and Phe-114 
are known to play an important role in S-warfarin binding to CYP2C9 based on 
mutagenesis studies 13. Supporting this theory is the fact that Asn-293 plays an additional 
role in maintaining overall tertiary structure 5. Residue 289 is an isoleucine in CYP2C19, 
which lacks the ability to metabolize the CYP2C9 substrate diclofenac, yet substitution of 
asparagine in place of Ile-289 confers that ability to CYP2C19 14, as well as enables the 
enzyme to bind tightly to CYP2C9-selective inhibitor sulphaphenazole 15, which further 
cements Asn-289 as a residue of importance in CYP2C9. 
 Another highly-conserved arginine, Arg-97, lies within the same flexible helix 
region that Arg-108 does, and is in close proximity to the heme propionate groups. In one 
study it was found that mutation to alanine increases the Km of diclofenac metabolism 
13-fold but does not alter Vmax 
16. Another study involving ARG-97A mutagenesis 
concluded that Arg-97 plays a primarily structural role in retaining the heme moiety 
within the tertiary structure of the enzyme after observing a marked decrease in 
holoenzyme expression of ARG-97 mutants 17. 
 11 
 Despite the presence of several charged residues, the active site retains an overall 
hydrophobic character. Residues shown to interact with CYP2C9 substrates warfarin and 
flurbiprofen are Val-113, Phe-114, Leu-208, Ile-205, Leu-366, Phe-100, Phe-476 12, 18, 19. 
It is likely that given the tendency of CYP2C9 substrates to possess a high degree of 
aromaticity, which tends to confer hydrophobicity, at least some of these residues likely 
play a role in the substrate binding. 
 Water molecules in the active site are known to play a critical role in the P450 
cycle 3. Wester et al. identified three water molecules present in the active site of their x-
ray crystal of CYP2C9 and  bound substrate flurbiprofen; one of which is positioned near 
the C-terminus. Another crystallized water occupies a site near Thr-301 along the I-helix. 
The third sits between flurbiprofen and the heme iron at a distance of 2.4 Å away from 
the iron and 3.0 A from the 4' hydrogen of flurbiprofen (the site of oxidation). This is 
consistent with experimental evidence in that flurbiprofen induces only a partial spin-
state change in the heme iron upon binding, indicating that it does not entirely displace 
the water molecule originally bound there 12. Locuson and Tracy identified seven 
conserved protein-water binding sites within or near the active sites of several 
mammalian P450 isozymes including CYP2C9 20. Of the three active site waters 
identified by Wester only one, located proximal to the I-helix, was determined by 
Locuson and Tracy to occupy a high-density water binding site. The remaining non-
heme-bound water in the crystal may be an artifact of the crystallization process, or it 
may play a role in sterically preventing the escape of the substrate once bound inside the 
active site, or play a role in the proton shuttle.  
 CYP2C9 is responsible for several known clinically relevant adverse drug-drug 
 12 
interactions. Some examples are diclofenac 4'hydroxylation inhibition by fluvastatin 21; 
fluconazole inhibition of losartan metabolism 22; inhibition of phenytoin metabolism by 
isoniazid 23; and probenecid inhibition of naproxen demethylation 24, to name a few. 
These interactions can have especially severe repercussions for the patient when drugs 
with narrow therapeutic windows are involved. For example, warfarin, a potent blood 
thinner, is potentiated by fenofibrate 25, fluconazole 26; and amiodarone 27 due to their 
ability to inhibit warfarin hydroxylation by CYP2C9. 
 
1.2. Kinetics of CYP2C9 
 Kinetic profiles are used to determine the intrinsic clearance of a drug, and hence 
the appropriate dosage in vivo. Due to the fact that the metabolism of a large number of 
xenobiotics falls mainly to only three subfamiles of CYPs (CYP3A4, 2D6, and 2C9), 
accurate estimation of intrinsic clearance is imperative. Miscalculation can put the patient 
at an increased risk of potentially adverse drug-drug interactions. Adding further 
complication is the fact that the effect one compound has on the metabolism of another is 
substrate-specific, and a compound that may be an activator for one substrate may in fact 
inhibit another. Clinically relevant problems arise when in vitro-in vivo correlative assays 
assume interactions occur between only one compound-- the substrate-- and the enzyme 
at any given time. A hyperbolic kinetic profile obtained for an enzyme-substrate system 
in vitro can become atypical in clinical trials when the participants simultaneously ingest 
other drugs to treat other maladies. This unforeseen change in drug kinetic parameters 
can result in adverse drug interactions that may persist even after cessation of treatment, 
particularly involving drugs with long half-lives.  
 13 
 Under most circumstances CYP2C9, along with other CYP isozymes, displays 
classical Michaelis-Menten kinetics (equation 1.1.), 
 
Vmax =  Km [S]                   (1.1.) 
           Km  + [S] 
  
where Vmax is the maximum rate of substrate turnover, Km is the binding affinity constant, 
and [S] is the substrate concentration. Enzyme-substrate systems displaying classical 
kinetics will yield a hyperbolic curve when velocity is plotted as a function of substrate 
concentration (Figure 1.5) Certain conditions, such as high substrate or salt 
concentrations, may result in CYP2C9 displaying atypical kinetics 28, 29, however, a 
common cause of non-hyperbolic kinetics is allosterism, in which two compounds, either 
two molecules of substrate or of a substrate and an effector molecule, simultaneously 
bind to the enzyme. This allosteric phenomenon can lead to inhibition of substrate 
metabolism, biphasic kinetics, or activation of metabolism. Allosterism can not only 
cause drugs with a Michaelis-Menten profile to become kinetically atypical, but can also  
 14 
 
 
 
 
Figure 1.5. Enzyme Kinetic Profiles. 
Enzyme kinetic profiles are illustrated by velocity curves and Eadie-Hoffstee plots 
(insets). From Atkins 30. 
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result in causing drugs known to possess an atypical kinetic profile to exhibit Michaelis-
Menten kinetics. 
 One specific type of atypical kinetics is heterotropic positive cooperativity, also 
called heteroactivation, which is a form of allosterism in which a substrate and an 
effector compound bind simultaneously to the enzyme, resulting in increased substrate 
turnover. The effector compound itself is rarely metabolized, or forms very little 
metabolite. A model example of this phenomenon is dapsone activation of flurbiprofen 
metabolism by CYP2C9. Dapsone is used in the treatment of leprosy and in certain types 
of pneumonia peculiar to AIDS patients. Flurbiprofen is a non-steroidal anti-
inflammatory drug (NSAID). Both are, individually, substrates of CYP2C9, forming N-
hydroxydapsone and 4'-hydroxyflurbiprofen as metabolites, respectively. However, in the 
presence of dapsone, the rate of flurbiprofen 4'-hydroxylation increases by roughly 64% 
compared to flurbiprofen metabolism in the absence of dapsone, while the Km decreases. 
Flurbiprofen has no effect on dapsone metabolism 31-33.  
 Polymorphism can determine the extent to which heteroactivation-related drug 
interactions will occur, or even if they will occur or not. Certain CYP2C9 variants also 
exhibit heteroactivation of flurbiprofen activation in the presence of dapsone. In the wild-
type, dapsone activates flurbiprofen oxidation by about 64% compared to the rate of 
metabolism of flurbiprofen in the absence of dapsone. However, in CYP2C9*2 and *5 
that figure increases to nearly 400%. CYP2C9*3 shows a nearly 1000% increase. Due to 
the poor oxidative ability of these three variants, the presence of dapsone may increase 
their ability to metabolize flurbiprofen at a rate more similar to that of the wild-type.  
[J.S. Aguilar, unpublished results]. In an other example, benzbromarone inhibits 
 16 
flurbiprofen 4'-hydroxylation in wild-type CYP2C9, but  activates flurbiprofen oxidation 
in the *3 variant 34. 
 As with many forms of atypical kinetics, the mechanism(s) of heteroactivation is 
not well- understood, and accurate prediction of effector potential based on 
physicochemical attributes of compounds is not generally possible. Theories regarding 
the mechanism(s) of heteroactivation vary. Evidence of a simultaneous presence of two 
compounds in the active site of CYP3A4 and BM3 had been in existence since the mid 
1990's 33, 35-37, and it was proposed that this could be the case in CYP2C9 as well. Recent 
NMR studies have indeed shown dapsone and flurbiprofen bound simultaneously within 
the active site of CYP2C9. In addition, the distance between 4'-hydrogen of flurbiprofen 
and the heme iron decreased by 0.90 A in the presence of dapsone compared to 
flurbiprofen alone 38. By building on this and other previously published data our goal is 
to better understand the mechanism(s) behind the phenomenon of heteroactivation and 
develop a predictive computational model capable of identifying as yet unknown effector 
compounds. 
 
1.3. Predictive Computational Models of Heteroactivation in CYP2C9 
 Atypical kinetics in CYP2C9 is difficult to anticipate due to the fact that no link 
between compound activity and physicochemical properties has yet been discovered 39. 
Heteroactivation is one of the more difficult forms of atypical kinetics to predict. High-
throughput in vitro assays designed to screen for compounds that cause non-classical 
kinetic profiles in CYPs are difficult to develop for heteroactivation, as it is practically 
impossible to screen every lead compound through an assay with every other therapeutic 
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already available. Often a lead compound has made its way through the drug design and 
development pipeline to the clinical phase before its effector potential is discovered, 
possibly resulting in its withdrawal from development and a wasted investment of both 
time and money of the pharmaceutical company.  
 Computational quantitative structure-activity relationship (QSAR) models are 
highly sophisticated and are useful for identifying key active site interactions responsible 
for metabolic activity that may elude visual analysis. Once these interactions are 
ascertained, a virtual high-throughput screening (vHTS or simply HTS) model can be 
developed to mine large databases of drug-like compounds for possible effectors. Thus, 
effector compounds can be identified at the beginning of lead compound design, saving 
time and money.  
 Prior to this work a comparative molecular field analysis (CoMFA) model had 
been developed by aligning dapsone and a series of dapsone analogs whose in vitro 
effector behavior was known. The alignment best correlating with in vitro activation of 
flurbiprofen oxidation was on the sulfone group. This model yielded a high correlation 
coefficient of determination (R2 = 0.80), and descriptors important in the alignment were 
identified as sterics, x, y, and z components of the dipole and the total dipole of the 
system, and electrostatics [J.S. Aguilar, unpublished results]. While the correlation was 
satisfactory, the CoMFA technique does not lend itself to HTS. 
 Only one successful HTS model specific to CYP2C0 heteroactivation has been 
developed to date. Using the program Glide 40, 41, a database of around 70,000 drug-like 
compounds was screened using a receptor structure consisting of CYP2C9 with substrate 
flurbiprofen docked in the active site. The top three confomers of the screened 
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compounds that scored below a certain energy threshold, and that had bound to a non-
substrate binding site inside the enzyme were tested in vitro for activity on flurbiprofen 
metabolism by CYP2C9. The model was able to identify three weak activators of 
flurbiprofen metabolism by CYP2C9, as well as a then-unknown effector compound 
similar to dapsone in activation capacity, yet very structurally dissimilar to dapsone 42. 
However, though the screening itself was fully automated, the process of identifying the 
effector compound using the binding modes of the flagged compounds was very user-
intensive. While the model is good, the amount of human involvement in the process may 
render the methodology somewhat inefficient, particularly for large databases with 
hundreds of thousands of compounds. 
 The model can be improved to the point that the human element in screening can 
be lessened to a manageable amount by understanding the mechanism(s) of 
heteroactivation and weighting key parameters in the screening program accordingly. 
Computational screening models have been developed for 3A4 heteroactivation with 
relative success 43, suggesting that it is possible for CYP2C9.  
 
1.4. Research Objectives 
 
1.4.1. Overview 
 Computer modeling has been successfully applied to problems of lead compound 
generation and enzyme-drug interaction prediction 44. The same methods are applicable 
to the development of models for the use of predicting enzyme-substrate-effector 
combinations. Here, we have used data from kinetic, structural, mutational and active site 
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interactions, to develop a model that can predict the potential for a compound to interact 
cooperatively with an enzyme-substrate complex. In pursuit of this goal three aspects of 
modeling were explored and integrated: effector docking to identify likely effector-
substrate-enzyme interactions, molecular dynamics to observe these interactions over a 
period of time, and high-throughput screening (HTS) of a large, external database 
following development of a statistical model using data obtained via the two techniques 
mentioned above, which involves the application of statistical methods to correctly 
weight certain interactions (i.e. “descriptors") over others for the purpose of increasing 
predictive power and validate the resulting model. Upon completion of the work the 
expected outcome is a computer model capable of screening large drug databases and 
identifying as-yet unknown activators of flurbiprofen metabolism by CYP2C9.  
 
1.4.2. Investigating Effector-Substrate-Enzyme Interactions by Docking 
 Docking is a fast and computationally cost-effective method of identifying binding 
modes for known substrates and inhibitors. By observing effector-substrate-enzyme 
interactions present in the docking results, docking a series of substrates into a CYP2C9-
flurbiprofen receptor complex may reveal which descriptors are the most important for 
biological activity. Such information can later aid in directing the training of the receptor 
to weight these descriptors over others.  
 Docking has been used successfully in the development of several statistical models 
of CYP2C9 metabolism 42, 43, 45-51; its popularity due in large part to its low computational 
cost and its speed when screening large databases. However, a major drawback of 
docking is the fact that speed in computation requires some sacrifice of accuracy. For 
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example, in programs capable of high-volume screening the receptor must be held rigid 
in order to achieve cost-effectiveness, which can impair model development when the 
ligand requires a conformational change in the enzyme to bind correctly. This issue may 
be circumvented somewhat by using the most representative structure of the receptor 
(obtained from molecular dynamics simulations performed with the ligand bound in the 
active site), but this tactic is still no replacement for true flexibility, and the results of the 
docking run will inevitably reflect this shortcoming to at least some extent. Despite the 
drawbacks of this methodology, it was expected that binding modes determined by the 
docking program would be accurate to a sufficient degree that it would be possible to 
visually identify interactions present in the active site.  
 
1.4.3. Investigating Effector-Substrate-Enzyme Interactions by Molecular Dynamics 
 Molecular dynamics (MD) simulations can be used to gain more detailed and 
accurate insight into receptor-ligand interactions. This method can allow full flexibility of 
the receptor, which may result in the discovery of active site interactions undetectable 
when the receptor is in a static state. Similarly, interactions identified by the docking 
program can be supported or refuted by MD. One of the most important advantages of 
using molecular dynamics is the ability to observe flexible receptor-ligand interactions. In 
addition, whereas docking programs output a static "snapshot" of the most likely binding 
mode of a ligand, in MD simulations the formation and dissolution of ligand-receptor 
interactions occur as a function of time. The addition of vector movement to all atoms in 
the system being investigated can be a major factor in determining the correct 
interactions when the receptor undergoes significant conformational change upon 
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binding.  
 A major disadvantage to MD, however, is that the cost in computation required to 
simulate the dynamic behavior of all atoms in both ligand and receptor (as well as 
individual water molecules in a solvated system) can be prohibitively large, and is 
therefore also very time-consuming. Because simulations of larger systems such as those 
involving whole enzymes can take up to three weeks or more, performing MD on a large 
number of compounds is not feasible. For these reasons dapsone alone was used as a 
representative of the training set and subjected to MD. NMR studies conducted prior to 
this work 38 established a relationship between the concomitant presence of dapsone in 
the active site of CYP2C9 and a decrease in distance between the site of oxidation of 
flurbiprofen to the heme iron. It was hypothesized that a MD simulation of CYP2C9 with 
flurbiprofen and dapsone both present in the active site would support the NMR findings, 
as well as illuminate specific effector-substrate-enzyme interactions responsible for them. 
 
1.4.4. Statistical Model Development and External Database Screening 
 Unweighted scores for each docked effector calculated by both docking programs 
would undergo regression analysis to determine which docking program yields the best 
correlation with the in vitro/CoMFA-predicted biological activities. That program would 
then be used to generate a predictive statistical model. To this end, a correlation 
coefficient of determination (R2) of  > 0.50 would be deemed sufficient 42, 43, 45-51. For it 
to possess maximum predictive power, the model must be "trained" to weight important 
descriptors, which can be difficult and time-consuming, especially when the descriptors 
themselves may not actually be as important to the biological phenomenon as the binding 
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mode can lead the user to believe; in other words, the user must refine the model such 
that truly important descriptors are dominant over the "noise". Weight adjustment can be 
accomplished by either manually altering specific parameter files used by the docking 
program or by using an automated weighting function native to the program. "Signal-to-
noise" ratio can be increased by one of many cross-validation techniques, such as leave-
x-out algorithms or permuting training set biological activities, both of which are 
described in detail in Chapter VI. Weight training and cross-validation would be repeated 
until an R2 of > 0.60 was achieved. Ultimately, once the statistical requirements have 
been met, the model can be validated by screening an external database, such as the 
National Cancer Institute (NCI) database of drug-like compounds. When screened, 
compounds identified by the docking program as probable activators of flurbiprofen 
metabolism by CYP2C9 would then be tested for their biological activity in vitro. 
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2.1 Introduction to In Silico Modeling of Atypical Kinetics in CYP2C9. 
 
 Unforeseen clinical complications involving ADMET (Absorption, Distribution, 
Metabolism, Excretion, Toxicity) properties of a new drug are problematic for 
pharmaceutical companies, who spend an estimated $800 million per year and an average 
of 12 years 52 on the discovery and development of a lead compound. Of particular 
concern are atypical metabolic profiles, which can result in adverse drug-drug 
interactions and can be difficult to predict using in vitro HTS (high throughput screening) 
methods. The development of predictive statistical models of enzyme behavior in silico 
can allow early identification of potential problematic lead compounds at the beginning 
stages of drug discovery, reducing monetary, temporal, and labor-related costs. However, 
developing statistically valid HTS models with predictive power sufficient to maintain an 
acceptably low number of false positives / negatives has proven difficult 53. The majority 
of in silico kinetic models are concerned with inhibition 46, 48, 54-56; few have been 
developed for activation 42, 49.  
 In silico statistical model-building requires some knowledge of either the nature 
of the receptor binding site or the characteristics of ligands that bind to the receptor. As a 
result, in silico HTS models and the techniques used to generate them can be generally 
divided into three categories: ligand-based, ligand-receptor-based, and receptor-based. 
The ligand-based techniques are often employed before the other two, when little to 
nothing is known regarding a particular metabolic phenomenon besides the structures of 
the compounds responsible for it. Therefore, early models of CYP2C9 atypical kinetics 
were generated using ligand-based techniques. Ligand-receptor-based models appeared 
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when homology models of CYP2C9 were developed. However, because homology 
models are not experimentally determined and thus may be lacking in structural accuracy, 
statistical models of metabolism generated using them were often corroborated by 
developing the same statistical model via the time-tested ligand-based methods. When x-
ray crystal structures of CYP2C9 were solved, these experimentally determined enzyme 
structures were reliable enough that they could, if desired, be used to the exclusion of 
ligand-based methods.  
 
2.2 Ligand-Based Models  
 
 Due to the dearth of reliable 3D receptor structures, ligand-based models-- also 
known as pharmacophores-- are the most plentiful in silico models of P450 kinetic 
behavior. A pharmacophore is defined as a set of descriptors, usually three or four 57, 
arranged in a specific geometry that are responsible for receptor interactions leading to a 
particular enzyme behavior. Pharmacophores have been developed for several CYP 
isoforms including 2D6 58, 59, 3A4 60-63, 2A6 64-66, and 1A2 67-70, but here the focus will be 
on 2C9. 
 One of the first predictive pharmacophore models of atypical kinetics in CYP2C9 
was developed by Ekins et al. in 2000 71. In addition to producing a 3D-QSAR, in which 
static compounds are aligned, this study also produced a 4D-QSAR, in which aligned 
compounds are allowed torsional freedom in order to obtain a superior alignment. The 
team constructed three initial pharmacophore models in Catalyst (Molecular Simulations, 
San Diego, CA), each built using a different training set. Multiple models composed of 
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multiple, diverse training sets increases the odds of discovering multiple and varied 
descriptors responsible for effector activity, which in this case was inhibition.  
 Model 1 used 9 inhibitors of tolbutamide 4-hydroxylation and diclofenac 4'-
hydroxylation. These compounds were structurally diverse but had similar degrees of 
inhibition, differing by only 27-fold. This model produced four features presumed 
requisite for inhibition of diclofenac and tolbutamide metabolism: two hydrophobic 
groups, one hydrogen bond donor, and one hydrogen bond acceptor (Figure 2.1).  
 Model 2 was developed using 29 inhibitors of S-warfarin 7-hydroxylation, which 
had a greater degree of structural similarity than compounds used in Model 1, but whose 
inhibitor activities spanned two orders of magnitude. The resulting pharmacophore 
identified four features necessary for inhibition: one hydrophobic group, two hydrogen 
bond donors, and one hydrogen bond acceptor (Figure 2.2).  
 A third model was built using phenytoin- and bis-triazole-analogs of tolbutamide 
4-hydroxylation, whose catalytic activities spanned only one order of magnitude. This 
model was therefore neither structurally diverse nor broad in range of activity. Model 3 
produced three necessary features for inhibition: one hydrophobic group and two 
hydrogen bond acceptors. Interestingly, one hydrogen bond acceptor and one 
hydrophobic group were traits that were conserved in all three models (Figure 2.3).  
 All pharmacophores were validated in three ways: randomizing the inhibitors' 
activities with their structures (meaning that each given biological activity value was 
randomly assigned to a structure) and repeating pharmacophore generation; screening a  
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Figure 2.1. Pharmacophore Model 1. 
Hydrophobic areas (cyan), hydrogen bond donor (HBD, purple), and a hydrogen bond 
acceptor feature (HBA, green) and a vector in the direction of the putative hydrogen bond 
donor are illustrated. From Ekins et al., 2000. 
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Figure 2.2. Pharmacophore Model 2. 
Hydrophobic areas (cyan), hydrogen bond donor (HBD, purple), and a hydrogen bond 
acceptor feature (HBA, green) and a vector in the direction of the putative hydrogen bond 
donor are shown. From Ekins et al., 2000. 
 
 
 
 
 
 
 
 29 
 
Figure 2.3. Pharmacophore Model 3. 
Hydrophobic areas (cyan) and a hydrogen bond acceptor feature (HBA, green) and a 
vector in the direction of the putative hydrogen bond donor are illustrated. From Ekins et 
al., 2000. 
 
 
 
 
 
 
 
 
 30 
test set of 14 inhibitors with known Ki values against the pharmacophore and conducting 
a partial least squares (PLS) calculation using a leave-one-out (LOO) algorithm, and a 
PLS calculation using a five-random-groups (5RG) algorithm repeated 100 times (5RG x 
100). Activity permuting of the inhibitors in Model 1 resulted in a pharmacophore with a 
total energy cost similar to that of the null hypothesis (which states that there is no 
relationship between the pharmacophore generated and the activities of the compounds 
used to build it), indicating that any relationship that may be found between the data and 
the inhibitors' activities was likely only due to chance.  
 The Pearson's coefficient had decreased compared to that of the original Model 1, 
which would be expected in a non-predictive pharmacophore, and further suggests that 
the structure-activity-relationship in Model 1 is valid and not simply due to chance. 
However, the same descriptors were identified in this "null" pharmacophore as in the 
original Model 1; for a model to be considered valid its descriptors ought to differ from 
those of the null pharmacophore. In Model 2, the correlation coefficient decreased, the 
total energy costs of the null hypothesis and the permuted-activity model were the same, 
and their respective descriptors were different. Permuted-activity Model 3 had different 
descriptors and a lower Pearson's coefficient, but its total energy cost was not close to 
that of the null hypothesis. In Model 1, 12 of the 14 inhibitors were correctly predicted 
within 1 log unit residual using the fast fit function of Catalyst. In Model 2, 10 of 14 
compounds were predicted within 1 log residual, also using the fast fit function. Allowing 
torsional rotation of the training set compounds (4D-QSAR) resulted in a LOO cross-
validated correlation coefficient (q2) of 0.54 for Model 1; the 3D-QSAR LOO q2 was 
lower, at 0.40. In Model 2 the 4D LOO q2 was 0.64. A q2 greater than or equal to 0.30 is 
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considered significant at the 95% confidence limit 72. This was a great improvement over 
the 3D LOO q2, which was statistically insignificant due to the fact that it's q2 value was 
less than 0.30. Model 3 did not generate a significant 3D nor 4D LOO q2 value.  
 Validation with the 5RG x 100 algorithm is considered to be more credible than 
LOO, as the number of R2 values used in calculating q2 is not limited to the number of 
compounds in the test set as it is in LOO. 4D 5RG x 100 yielded a q2 of 0.55 for Model 2, 
compared to an insignificant 3D 5RG x 100 q2 value. The 4D approach did not improve 
the 5RG x 100 q2 in Model 3, however, its 3D 5RG x 100 q2 was significant, at 0.50. No 
significant 5RG x 100 q2 could be obtained for Model 1 using either 3D nor 4D 
algorithms. The superior q2 obtained from several 4D pharmacophores suggests that the 
rigid aligned confomer used in 3D-QSAR is not necessarily the most likely conformation 
of an effector compound. The study demonstrated that 4D QSAR may improve some 
models (as it did in Models 1 and 3), but actually reduced the predictive power of others. 
In addition, it appeared that different method of model validation can yield different 
results when determining models' significance. For example in Model 1, where the 5RG x 
100 algorithm did not yield a significant correlation coefficient, but the LOO method did. 
 Another early predictive CYP2C9 pharmacophore was developed in 2001 by Rao 
et al. 54, and also modeled CYP2C9 inhibition of S-warfarin 7-hydroxylation. This 
CoMFA model consisted of 27 coumarin analogs, sulfonamides, carboxylate-containing 
drugs, and phenytoin. The training set compounds were manually aligned, allowing 
manual torsional rotation to obtain better superimposition. Manual alignment enabled the 
team to conform their model to complement site-directed mutagenesis studies as well as a 
homology model of CYP2C9 (at the time there was no x-ray crystal structure), which had 
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identified possible pi-stacking interactions between Phe-114 and aromatic rings of the 
inhibitor compounds. Sulfaphenazole, an outlier in an earlier CoMFA model by the same 
researchers, was presumed to interact with a positively charged residue; the LOO q2 
calculated when including sulfaphenazole in the model was 0.70. Interestingly, re-
aligning sulfaphenazole in such a way that its aniline ring could pi-stack with Phe-114 
prevented any electrostatic interaction with the protein, but the LOO q2 calculated from 
this model was 0.72, suggesting that pi-stacking in this case may be at least as important 
as electrostatics in sulfaphenazole active site binding.  
 Descriptors deemed important in inhibitor binding identified by the re-aligned 
pharmacophore were a single strong negative charge interaction and one or two positive 
charge interactions. Hydrophobic interactions were not included in the CoMFA model, 
despite the data obtained from re-aligning sulfaphenazole. A test set of 14 compounds (10 
of which were sulfonamides) that were not included in the training set was screened 
against the pharmacophore, which was able to predict the biological activities of the test 
set compounds in the words of the author to a “reasonable degree of accuracy”. Four 
sulfonamides were then arbitrarily selected from the test set and were included with the 
original training set to produce a new pharmacophore. This new model was used to 
screen the remaining 10 of the original 14 test set compounds, with the result of an 
increased ability of the model to predict sulfonamide activities. A final pharmacophore 
was developed by combining the original training set and all test set compounds, a total 
of 41 compounds. This model yielded a LOO q2 of 0.65 when the original test set of 14 
inhibitors was screened against it. All pharmacophores were cross-validated using PLS 
and a LOO algorithm, as well as a leave-20%-out algorithm, and by permuting biological 
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activities of the inhibitors in the test and training sets. For all pharmacophores the leave-
20%-out method produced q2 values similar to those calculated using the LOO method. 
Randomly assigning binding affinities of compounds used in the training sets resulted in 
pharmacophores with negative q2 values, supporting the validity of the actual 
pharmacophore models developed by the researchers. The main value of this work lay in 
its ability to correctly identify potential active site interactions and binding modes of two 
structural classes of compounds (coumarin analogs and sulfonamides) in an enzyme 
structure that did not exist at the time, since no homology model nor crystal structure had 
yet been published. Also, this is the first in silico  study involving CYP2C9 to explore the 
possibility of pi-stacking interactions as important to effector binding in the active site. 
 Locuson et al. conducted a study investigating inhibition of CYP2C9-mediated S-
warfarin 7-hydroxylation by benzbromarone analogs 73. Here, by employing CoMFA and 
CoMSIA methodology, the team sought to accomplish three goals: 1) determine the 
degree to which anionic character affected benzbromarone analog binding affinity to 
CYP2C9, 2) develop a predictive pharmacophore for the purpose of screening unknown 
compounds that may precipitate drug-drug interactions, and 3) use the pharmacophore to 
identify active site residues contributing to specific interactions predicted by the 
pharmacophore. The latter was also useful for helping to verify residue conformations 
and the ligand binding mode in an x-ray crystal structure of CYP2C9 bound with s-
warfarin, to distinguish what aspects of the crystal structure are likely to be artifacts of 
the crystallographic process. To build the initial pharmacophore, 17 minimized 
benzbromarone analogs with known binding affinity constants were aligned such that the 
primary site of oxidation, electronegative oxygens, and aromatic ring corresponding to 
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the brominated ring of benzbromarone were superimposed on s-warfarin. Torsions were 
manually adjusted for better overlap. These compounds were very similar in structure, 
but had activities ranging over three orders of magnitude. Five of the 17 analogs were 
anionic at physiologic pH, and both a neutral (fully protonated) training set and an 
anionic training set were used in pharmacophore generation to ascertain the importance 
of the role anionic character played in binding affinity.  
 Pharmacophores were made using both CoMFA and CoMSIA methods. CoMSIA 
differs from CoMFA in that it indexes the training set compounds by structural similarity 
and derives its descriptor fields from this rather than from calculating dipole moments. 
The models were cross-validated via a LOO algorithm and by assigning permuted 
biological activities to the training set. Negative q2 values were calculated for the 
pharmacophore composed of permuted affinity constants, which indicates a 
pharmacophore that has no correlation with the data used in its construction, and bolsters 
the argument that the pharmacophores built using correct binding constants were not due 
to chance. LOO q2 values were greater than 0.30 for all pharmacophores, further adding 
to the statistical validity of the models. Contour plots of the CoMFA models of both 
anionic and neutral training sets revealed that formal charge state was not an important 
factor for predictivity; the neutral test set generated a q2 of 0.54 compared to the anionic 
set's 0.49, indicating a greater capability for accurate Ki prediction in the neutral set. The 
CoMFA models, which only calculated electrostatic and steric descriptors, predicted 
unfavorable steric interactions around the C-2 position of benzbromarone (Figure 2.4).  
 Analogs containing C-2 substituents had progressively lower affinities as the 
substituent size increased. According to the CoMFA data, benzbromarone analog binding  
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Figure 2.4. Chemical Structure of Benzbromarone. 
Numbering scheme of benzbromarone used in the text is shown. The site of oxidation by 
CYP2C9 is designated by the arrow. From Locuson et al., 2004. 
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affinity could be attributed 40-46% to electrostatics, and 54-60% to sterics. There was no 
major difference in descriptors between the anionic and neutral CoMFA-generated 
pharmacophores, which further eroded the importance of formal state charge  to binding 
affinity. CoMSIA-generated pharmacophores assessed not only sterics and electrostatics, 
but also hydrophobicity. In these models, a favorable hydrophobic interaction was 
predicted to exist above the bromated ring of benzbromarone. It was also noted that a 
CoMSIA model only including electrostatics and hydrophobicity produced better q2 
values (0.61 for the anionic training set, 0.60 for the neutral set) than a model including 
only electrostatics and sterics (0.48 for the anionic set, 0.61 for the neutral set). This 
implies that sterics are not as important a factor in binding affinity. Rather, that 
hydrophobicity and electrostatics are the driving forces in this case. However, sterics did 
play a greater role in the binding of a few benzbromarone analogs; compounds that 
lacked a formal negative charge but that were still somewhat acidic in nature had greater 
affinity if they contained bulky substituents on what corresponded to the brominated ring 
of benzbromarone than comparable analogs (Figure 2.5) devoid of the bulky groups. In 
addition, their binding affinities were only marginally less than formally anionic 
inhibitors. Warfarins, NSAIDs, and sulfaphenazoles were added to the set of 
benzbromarone analogs, which increased the structural diversity of the training set and 
brought the total number of compounds used to 58. These compounds were aligned in the 
same fashion as the 17 original molecules.  
 The resulting CoMSIA models agreed with the original, smaller models in that 
hydrophobicity was of greater importance to binding affinity than sterics. This was made 
apparent by the increase in q2 from 0.64 in an electrostatics/sterics-only model to 0.75 in  
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Figure 2.5. Chemical Structures of Benzbromarone Analogs. 
Chemical structures used to develop the model are shown. From Locuson et al., 2004. 
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an electrostatics/sterics/hydrophobicity model. This pharmacophore predicted a favorable 
electrostatic interaction at the ketone of benzbromarone, which overlaid well upon 
oxygens belonging to sulfaphenazole and warfarin and suggested that a sufficiently 
electronegative functional group placed there would aid to increase the analog's binding 
affinity. Therefore, a general conclusion can be drawn that compounds better able to 
become polarized and redistribute electron density to such a strategically located oxygen 
will have lower Ki values, even if they are not formally anionic.  
 At the time of this publication an x-ray crystal structure of CYP2C9 co-
crystallized with S-warfarin (1OG5) had become available 19. Contour plots of the 
pharmacophores could aid in identifying specific residues in the active site by 
superimposing them onto the crystal structure. Being a competitive inhibitor, 
benzbromarone may bind to the same site as warfarin does prior to its metabolism. 
However, in the crystal structure, warfarin was bound in a hydrophobic pocket with its 
site of oxidation 7 Å from the heme iron-- too great a distance for metabolism to occur. 
While the pharmacophore could be superimposed onto the crystal structure in this 
binding site and still have all of its descriptor criteria fulfilled, a second binding site 
within the same pocket but closer to the heme iron for catalysis, also fulfilled the 
descriptors identified by the CoMSIA/CoMFA results. Though the crystal structure 
suggested otherwise, this second site was more likely to be the actual metabolite-
producing binding site. In it, one favorable steric site was located near the site of warfarin 
metabolism, and when superimposed on the crystal structure lies nearly in contact with 
Phe-114, a residue known from mutagenesis studies to be important for metabolism in 
CYP2C9 19. Assuming benzbromarone takes a similar pose to that of warfarin in the 
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crystal structure, favorable hydrophobic interactions between benzbromarone and either 
Phe-114 or Phe-476 are possible, as well as favorable hydrophobic interactions between 
the inhibitor's bromine substituents (or an equally bulky group on a benzbromarone 
analog) and hydrophobic residues such as Leu-208. Phe-114 and Phe-476 have both been 
identified as residues important to CYP2C9 metabolism 13.  
 In 1OG5, Arg-108, which has been shown by mutagenesis studies to be critical to 
metabolism of several substrates by CYP2C9, including warfarin and benzbromarone 73 
is oriented such that its cationic side-chain is directed away from the active site (Figure 
2.6). This orientation is not conducive to productive substrate binding due to its large 
distance from the heme iron, however, given the geometry of the CoMSIA 
pharmacophore data, favorable hydrophobic interactions could occur between the 
benzoyl ring of benzbromarone and Phe-114 in a T-stacking geometry (Figure 2.7), 
which not only puts the site of metabolism about 3 Å directly above the heme iron, but 
also places its electronegative ketone oxygen 2.5 Å of an inward-facing side chain 
ammonium of Arg-108. It was postulated that perhaps the outward-facing, crystallized 
orientation of Arg-108 may be the result of high protein flexibility in that region, or even 
an artifact of the crystallization process. Later another crystal structure was released 12, in 
which flurbiprofen was bound in a productive pose with its anionic carboxylate group H-
bonded to the side-chain of Arg-108 (Figure 2.8). 
 Egnell et al. developed the only pharmacophore model of CYP2C9 
heteroactivation to date, using a test set of 36 inhibitors and activators of 7-methoxy-4-
trifluoromethyl-coumarin (MFC) 49. Due to the lack of mechanistic knowledge of  
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Figure 2.6. Arg-108 Conformation in 1OG5 Crystal Structure of CYP2C9. 
The crystal structure of 2C9 co-crystallized with s-warfarin by Williams et al.,  
ProteinDataBase code 1OG5 is shown. The substrate, warfarin, is in goldenrod and the 
heme is crimson. Note how the side chain of residue R108 is directed away from the 
active site cavity where it cannot readily interact with the substrate. From Williams et al., 
2003. 
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Figure 2.7. Pi-Stacking Geometries. 
Stacking geometries of aromatic rings are illustrated: A) sandwich stacking, B) T-
stacking, and C) displaced parallel stacking. From Sinnokrot et al., 2002 74. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 42 
 
Figure 2.8. Arg-108 Conformation in 1R9O Crystal Structure of CYP2C9. 
The crystal structure of 2C9 co-crystallized with flurbiprofen by Wester et al., 
ProteinDataBase code 1R9O is shown. The substrate, flurbiprofen is in goldenrod and the 
heme is crimson. Note how the side chain of residue R108 differs in orientation from that 
in the crystal structure by Williams (see Figure 2.6); here it comprises part of the active 
site topology and forms a hydrogen bond with the anionic carboxylate group of the 
substrate. 
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heteroactivation in 2C9, and hence an inability to calculate a pure heteroactivator affinity 
constant, v150% , the concentration of activator at which substrate turnover was 50% 
higher than vmax , was substituted as an endpoint to measure the degree of metabolic 
activation. The pharmacophore was generated in Catalyst using a test set of 36 
compounds that were either known activators or known inhibitors. Alignment of the test 
set compounds resulted in a pharmacophore that suggested hydrogen bond accepting 
groups, aromatic rings, and hydrophobic groups to be of prime importance for 
heteroactivation of MFC metabolism by CYP2C9. The correlation coefficient of 
determination, R2, was 0.50. Statistical validation was carried out using a LOO algorithm, 
as well as comparison of the total energy cost of the model to that of the null 
pharmacophore. A diverse database of 1504 compounds (including oral drugs and known 
P450 inhibitors) was screened against the pharmacophore. Thirty-seven of these were 
identified by the model as activators of CYP2C9-mediated MFC metabolism, with 
activation defined as an increase in metabolism greater than 20% at a concentration equal 
to or less than 125 µM. Among these were amiodarone, niclosamide, liothyronine, 
meclofenemate, zafirlukast, estropipate, dichlophenamide, hydroflumethiazide, 
mefenamic acid, and warfarin, all of which had v150% values at concentrations below 10 
µM. All identified compounds except for niclosamide were previously unknown 
activators of CYP2C9-mediated MFC metabolism. The top five most potent newly-
identified activators could be easily superimposed onto the pharmacophore, matching 
both its chemical and geometric descriptors. Though the model correctly identified strong 
activators and inhibitors, it failed to correctly quantify the heteroactivity of compounds 
with more moderate potency. The binary nature of this pharmacophore model may be in 
 44 
part due to the distribution of v150% values of the training set, which contained strong 
activators and inhibitors, but no compounds of moderate biological activity. 
 
2.3 Ligand-Receptor-Based Models 
 
 Both ligand-receptor- and receptor-based models require three-dimensional 
structures of both ligand(s) and receptor (enzyme), and are developed either by docking 
the ligand(s) into the active site or by applying a pharmacophore to the active site to 
identify specific residue interactions. For ligand-receptor-based methods receptor 
structures are usually obtained via  homology modeling. Homology modeling is used 
when no crystal structure is available for a particular enzyme, but one does exist for an 
enzyme with a high degree of sequence similarity. Generally speaking, the higher the 
percentage of sequence similarity, the more reliable the homology model will be 75. The 
technique involves sequence alignment of the template enzyme crystal structure with the 
target enzyme, substitution of homolog residues for template residues, and then energy-
minimizing the 3D geometry of the resulting structure. Prior to the development of 
CYP2C9 crystal structures, homology models of CYP2C9 were built using the crystal 
structure of CYP2C5 76, which shares a 77% sequence identity with CYP2C9, as a 
template. 
 The first study investigating atypical kinetics in CYP2C9 that involved homology 
modeling was conducted in 2000 by Afzelius et al 46. In this work both a 3D 
pharmacophore model and a homology model were constructed for 29 structurally 
diverse competitive inhibitors of diclofenac 4'-hydroxylation and 7-methoxy-4-
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trifluoromethylcoumarin demethylation. The crystal structure of rabbit CYP2C5 served 
as a template, and the alignment between the two enzymes was adjusted manually using 
the Homology module of InsightII. Overlaying the backbones of the two structures 
produced an RMSd of 0.18 Å. The inhibitor compounds were energy minimized and 
docked into the model with the docking program GOLD [Gareth Jones, University of 
Sheffield, UK]. Following this, a pharmacophore model was developed using the 
resulting lowest-energy docked confomers of 21 of the same set of 29 inhibitors. 
Electrostatic and hydrophobic interaction energies were calculated using the program 
GRID [Molecular Discovery Ltd., University of Oxford, UK], and were subjected to 
statistical analysis with GOLPE. GRID, as its name implies, calculates a topology of the 
active site with each grid point defined by a specific ligand-receptor interaction energy. 
Interactions whose overall energies were less than 0.02 kcal/mol were excluded from 
analysis, and the remaining interaction variables were clustered together based on their 
respective docked confomers' geometric similarity to s-warfarin, phenytoin, progesterone, 
and sulfaphenazole. These four substrates have a known mechanism of binding and/or 
site of hydroxylation by CYP2C9, and therefore any competitive inhibitor such as those 
in the training set would likely take on  a conformation similar to one of them when 
bound in the active site.  
 The eight compounds that were not used in the training set were used instead as a 
test set and were screened against the resulting pharmacophore. To test the validity of the 
pharmacophore model a LOO algorithm, a leave-20%-out algorithm, and a leave-50%-
out algorithm were implemented. The LOO method calculated a Pearson's correlation 
coefficient of 0.947 and a q2 of 0.730. The L-20%-O method yielded a q2 of 0.672, and 
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the L-50%-O method produced a q2 of 0.497. All of these q2 values exceed 0.30 and are 
therefore statistically significant. In addition, binding affinities of the test set predicted by 
the pharmacophore were within 0.5 log units of their respective experimental values. The 
importance of Afzelius' research here lay in the development of the first CYP2C9 
homology model, which enabled the future use of receptor-based methodologies for 
studying the enzyme's kinetics. The fact that a highly-predictive pharmacophore could be 
constructed using inhibitor confomers resulting from the homology model docking 
supported the accuracy of the homology model.  
 In a later study 47 Afzelius et al. conducted a very similar set of experiments, this 
time involving the use of a molecular descriptor-calculating tool called ALMOND [MIA, 
Perugia, Italy], which could process the docked ligand-receptor interactions predicted by 
GRID and compute which descriptors (i.e. hydrogen bond accepting, donating, or 
hydrophobic) were most involved in inhibitor binding. The methodology used in 
ALMOND did not require alignment of the inhibitor compounds, which circumvented the 
problems involved in trying to align a very structurally diverse set of compounds. 
Accurately predicting inhibition in CYP2C9 could be achieved, as could better 
understanding the mechanism by which inhibition occurred, using only one model.  
 Twenty-two inhibitors with known binding affinity constants were used as a 
training set and 12 additional inhibitors comprised the test set. Using the same methods 
employed in the first study, the compounds were docked into the active site of the 
CYP2C5-based homology model of CYP2C9. The GRID-calculated interactions of the 
resulting lowest-energy docked confomers were then input to ALMOND, which in turn 
calculated the most important descriptors based not only on the interaction energies 
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supplied by GRID, but also on the spatial distances between the atoms involved in those 
interactions. For each descriptor of every inhibitor the interaction with the lowest energy 
and whose participating atoms were within an arbitrary distance of one another was 
deemed the "maximum interaction", and a score was calculated by ALMOND using its 
energy as a function of distance. To validate the model, a PLS statistical analysis was 
conducted using both the LOO method and a random grouping algorithm, which ensured 
no one compound or group of compounds was driving the correlation. The analysis was 
performed for both the training set and the test set, correlating binding affinity constants 
with the ALMOND scores. For the 22-compound training set the correlation coefficient 
of determination was 0.81, the LOO q2 was 0.62, and the random grouping q2 was 0.59, 
indicating a model with significant predictive power. Binding affinities of nine out of 12 
of the test set compounds were predicted within 0.3 log units, and two others were 
predicted within 0.5 log units.  
 Because the interaction grid points formed a topology of the CYP2C9 active site 
it was possible to observe which residues were responsible for which interactions. For 
various inhibitors used in the study, several residues were strongly implicated in binding, 
including Phe-114, Phe-476, and Asp-293-- all of which have been shown experimentally 
to be important in the catalytic activity of CYP2C9 5, 13. The receptor-based methodology 
developed here made it possible to construct a predictive in silico kinetics model of 
CYP2C9 when prior knowledge of potential confomers of the compounds being screened 
is limited, and/or the breadth of structural diversity of the compounds is very wide. 
 
2.4 Receptor-Based Models 
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 Receptor-based models are generated using X-ray crystallographs (often referred 
to as "crystal structures"), which are preferred to homology models because that they are 
experimentally determined representations of the enzymes themselves. However, when 
modeling metabolism using crystal structures it is important to keep in mind that the 
structure may not be a perfect representation of enzymes in vivo. Crystallizing P450s is 
challenging due to the low solubility of the enzymes, and modifications such as mutating 
specific surface residues as well as truncating the hydrophobic N-terminal tail, which 
anchors the CYP to a cellular membrane. Crystal formation is also not undertaken at 
physiological conditions. The altered enzymes are tested in vitro to ensure that such 
modifications do not compromise catalytic activity, however, it is still possible that the 
overall conformation of the enzyme could be affected, which could in turn alter the 
mechanism of substrate metabolism. Two crystal structures have been solved for 
CYP2C9-- one co-crystallized with warfarin 19, and the other with flurbiprofen 12.  
 When Hummel et al. obtained NMR data proving that dapsone-mediated 
activation of flurbiprofen metabolism by CYP2C9 required the simultaneous presence of 
both effector and substrate in the active site 38, they conducted docking studies on another 
atypical kinetic system: benzbromarone inhibition of flurbiprofen metabolism in 
CYP2C9 77. Using MoViT v.8.0, in-house software developed by Pfizer, Inc. (LaJolla, 
CA), benzbromarone was docked into the crystal structure of CYP2C9 with flurbiprofen 
co-crystallized in the active site solved by Wester, and minimized to its lowest energy 
conformation. Flurbiprofen was excised from the crystal structure and re-docked into the 
active site to develop the final receptor structure. NMR data was used to orient both 
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flurbiprofen and benzbromarone in the active site prior to docking. Lowest-energy 
confomers of benzbromarone docked in two overlapping binding sites that were 
composed of the B-C loop, helices F,G, and I, and the C-terminal loop, which contains 
Phe476. Both of these possible effector binding sites are superimposable with that of 
dapsone when docked into the same receptor according to Wester. Another interesting 
note is that in the CYP2C9*3 variant benzbromarone changes from an inhibitor to an 
activator of flurbiprofen metabolism. MoViT requires a spatially fixed receptor, which 
eliminates the possibility of observing via docking whether or not the I359L mutation in 
the *3 variant would elicit a conformational change in the enzyme that would allow 
benzbromarone to dock in a conformation more conducive to encouraging flurbiprofen 
metabolism. (This could only be deduced via a very lengthy molecular dynamics 
simulation.) However, the docking results do show that sufficient space exists in the 
wild-type crystal structure as-is for both benzbromarone and flurbiprofen. Although 
Wester had already docked dapsone into this same receptor prior to this publication, 
Hummel's study reinforced Wester's findings and also suggested the role polymorphism 
may play in altering an effector's binding pose, causing it to change is effect on substrate 
metabolism. in the active site of CYP2C9, and aided in the identification of previously 
unknown effector binding sites within the greater active site of CYP2C9. 
 Kumar et al. built on the work done by Hummel, above, by including two 
amiodarone analogs in addition to benzbromarone. Amiodarone's effect on naproxen 
demethylation by CYP2C9 differs from that of three of its analogs, 
desmethylamiodarone, benzbromarone, and benz(meth)arone. In vitro, amiodarone 
activated naproxen demethylation at concentrations from 0.5 and 2.5 µM, but inhibited 
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metabolism at concentrations above 12.5 µM. In contrast, benz(meth)arone activated 
naproxen metabolism in both alleles, and benzbromarone activated naproxen metabolism 
in the wild-type but inhibited it in the variant. Both desmethylamiodarone and 
benzbromarone inhibited naproxen metabolism at any concentration, but 
benz(meth)arone actually activated naproxen demethylation. Benzbromarone and 
benz(meth)arone not only affected the substrate turnover rate but also altered the kinetic 
profile of naproxen metabolism from biphasic to hyperbolic. It was hypothesized that 
different binding modes may be the cause of the discrepancies in the effects the 
amiodarone analogs had on naproxen metabolism. Docking studies were performed with 
the program Glide (Schrödinger, LLC, Portland, OR). The receptors were developed 
using the x-ray crystal structure solved by Wester 12, and included CYP2C9-naproxen as 
well as CYP2C9-flurbiprofen and CYP2C9 alone as controls. Amiodarone, its three 
analogs, and naproxen were docked into the receptors and the top resulting scores and 
binding modes were compared. In the empty active site naproxen bound in a fashion 
similar to the co-crystallized flurbiprofen, with its methyl group-- the site of metabolism-
- pointing toward the heme and its carboxylate moiety interacting with Arg-108. 
Amiodarone and its analogs, which are themselves substrates of CYP2C9, also bound in 
the empty active site of CYP2C9 in conformations in agreement with the formation of 
their respective metabolites. When docked in the presence of naproxen, benz(meth)arone 
oriented itself in such a way that it interacted with Phe-476 via one of its aromatic ring 
systems. Benzbromarone docked in roughly the same location as benz(meth)arone, near 
recognition site 6, but its ring systems were oriented oppositely compared to those of 
benz(meth)arone. It was thought that part of the mechanism behind benz(meth)arone's 
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activation of naproxen demethylation involved its ability to interact with Phe-476 via pi-
stacking, which would hold the effector in place. Steric forces between benz(meth)arone 
and the substrate would crowd naproxen closer to the heme iron, thus increasing its rate 
of metabolism. Benzbromarone is a larger compound compared to benz(meth)arone due 
to its bromide groups; its size may restrict it to binding in such a way that it does not 
easily orient itself in a mode conducive to Phe-476 interaction and thus is not as readily 
stabilized in position inside the active site. In addition, benzbromarone is acidic at 
physiological pH, which may also play a role in determining its binding mode. This study 
was one of the few that computationally investigated atypical kinetics as a function of 
binding orientation in the active site of CYP2C9, and aided in the identification of 
specific effector-active site residue interactions that may be responsible for the effector's 
kinetics-altering properties. 
 Locuson et al. developed a screening protocol for activators of flurbiprofen 
metabolism in CYP2C9, also using Glide. Dapsone and nineteen of its analogs-- seven 
activators and twelve non-activators or inhibitors-- were chosen to develop the protocol 
based on their known in vitro effect on flurbiprofen metabolism and also due to their 
having a wide range of activities despite being structurally similar. The receptor was 
developed using Wester's x-ray crystal structure with flurbiprofen co-crystallized in the 
active site. Dapsone was docked into the active site along with flurbiprofen to act as a 
"placeholder" to prevent the active site from collapsing during the subsequent 2 ns 
molecular dynamics simulation using the Amber8 suite of modeling software. Molecular 
dynamics served to mitigate artifacts of the crystallization process that may affect 
enzyme conformation; the post-simulation structure would be more likely to accurately 
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reflect the enzyme conformation under physiological conditions. Dapsone was excised 
from the active site following the simulation, resulting in the finished receptor used for 
screening. The structures of the dapsone analog test set compounds were built and energy 
minimized using Sybyl 7.0 [Tripos, Inc., St. Louis, MO], and were docked into the active 
site using Glide and the top ten scored confomers for each effector were retained for 
analysis. No correlation was seen between the Glide scores and the degree of 
heteroactivation, however, the scores of the inhibitors tended to fall below that of the 
weakest activator. In addition, if flurbiprofen was removed from the receptor and the test 
set docked through the empty active site the compounds known to be activators preferred 
binding in a region occupied by dapsone during the molecular dynamics simulation (the 
"effector site") rather than the substrate binding pocket more proximal to the heme. The 
qualitative activities of five out of six heteroactivators were correctly predicted if one of 
the top three ligand conformations bound to the effector site. Using both the binding 
mode and the Glide score of the weakest activator as a cutoff, 11 out of 12 inhibitors 
were correctly predicted as such. To validate this method of effector activity prediction, 
the ZINC database 78 composed of drug-like compounds was chosen to be screened. The 
activities of the database compounds were unknown, and it was seeded with the 20 
compounds comprising the test set as a control. As preparation for docking, up to four 
stereoisomers were generated for chiral compounds in the database and were included in 
the screen. This extended database was sieved though a molecular weight filter using 
Sybyl to limit the size of the compounds to a range of 120-350 amu. Of the filtered 
database, alternate ionization states were built for those molecules containing functional 
groups whose pKa values were between 5 and 9. Energy minimization was the final step 
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in the preparation of the database which could now be used as a validation set. Docking 
was carried out in two steps: first, torsions were held rigid so that the ligands could not 
deviate from their already optimized geometry. This screening, which was performed 
with flurbiprofen simultaneously present in the active site to cull ligands whose size 
would exceed that required to fit into the active site with the substrate, eliminated 76% of 
the ZINC compounds. In the second step the remaining molecules were docked into the 
empty CYP2C9 active site and torsional restraints were removed so that rotamers would 
also be scored. The top ten binding modes for each docked compound were analyzed to 
assess their binding preferences: whether or not they preferred the effector site or the 
substrate site. Only compounds that bound to the effector site in at least the top two 
scored conformations were considered to be heteroactivators. Ten of these compounds-- 
four whose Glide scores were superior to and six whose Glide scores were inferior to that 
of dapsone-- were selected for in vitro analysis of their biological activities. One 
compound was found to activate flurbiprofen metabolism by CYP2C9 by 46%, which 
was comparable to the activating activity of dapsone and was statistically different from 
the DMSO control (p < 0.05). Four other compounds appeared to be weak activators but 
were not statistically different from the DMSO control. Three others were found to be 
inhibitors, and two had no effect on flurbiprofen metabolism even at concentrations as 
high as 10 mM.  
This was the first and at the time of this writing the only study to demonstrate that 
computational methods for the prediction of heteroactivation in CYP2C9 could be 
developed with success. It was also the first predictive computational method to identify 
a compound whose strong activating activity was unknown prior to this study. This 
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research also unearthed the presence of a specific binding site preferred by 
heteroactivators even when given the choice of docking in the substrate binding site, 
where favorable active site interactions are known to occur with compounds of similar 
chemical composition to the dapsone analogs. One drawback, however, is the amount of 
human involvement required to determine the binding mode for all compounds, which 
may be a limiting factor if the processed database to be screened is very large. Also, as 
with so many other models, the rigid receptor may cause many unknown activators to be 
missed, either because they exceed the space allotted in the active site during the first step 
of the screening process, or because residues that are required for activator binding may 
become part of the active site topology only with conformational change of the enzyme. 
 In conclusion, both pharmacophore and receptor-based modeling techniques have 
been used successfully to expand our understanding of the active site interactions 
responsible for atypical kinetics in CYP2C9. This work aims to build on that body of 
literature and add our own contribution to illuminating the mechanism(s) and predicting 
the likelihood of the occurrence of atypical kinetics, specifically heteroactivation. 
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CHAPTER III 
Molecular Dynamics Simulations of the CYP2C9-
Flurbiprofen Complex With and Without Dapsone 
Present 
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3.1. Introduction 
 
 Molecular dynamics simulation (MD) has been extensively used in a multitude of 
disciplines as a means of understanding the structural and dynamic behavioral properties 
of molecules at the atomic level. These include physics, engineering, chemistry, and 
biology. Molecular dynamics is generally considered to be a superior method compared 
to the Monte Carlo approach due to the greater amount of information the former 
provides; MD monitors fluctuations in the atoms' positions in three-dimensional space as 
well as their velocities per unit of time. (In contrast, the Monte Carlo method concerns 
itself primarily with a compound's spatial position without taking time dependence into 
account.)  
 These motions become increasingly manifold as the molecule grows in 
complexity, and macromolecules such as proteins display a broad range of characteristic 
motions. Essentially, they can be consolidated into three categories: local motion, 
medium-scale motion, and global motion. Local motion includes movement on the 
atomic level such as bond length, angle bending, and torsional rotation. The time-scale 
for such studies ranges from femtoseconds (10-15 s) to picoseconds (10-12 s). Examples of 
medium-scale motion are protein loop motion, rigid-body motion, and terminal-arm 
motion. Active site conformational changes and binding specificity are readily 
determined on this scale, which is typically in nanoseconds (10-9 s). The medium scale is 
the one most commonly employed by biological scientists, and certainly those studying 
enzymatic activity, as it offers a timescale sufficiently long for observing biological 
phenomena, but short enough so as to be computationally accessible. The third type of 
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motion is global motion, which encompasses protein folding/unfolding, subunit 
association, and helix-coil transition, operates on a timescale ranging from milliseconds 
(10-3 s) to hours (104 s). Though providing a great deal of information regarding overall 
protein functionality, this timescale is generally far too computationally expensive to 
have practical application, and is to-date never used for molecular dynamics. In this work 
we have chosen to use the medium scale, for the reasons indicated above. 
 In addition to an appropriate timescale, molecular dynamics simulations must 
possess a certain level of accuracy in order to be of practical use to scientists. The level of 
accuracy is determined by defining the equation of atomic motion in a Newtonian 
(classical) context, a stochastic context, or a context consisting of a mixture of quantum 
and classical mechanics (QM/MM). Unfortunately, accuracy is inversely proportional to 
computational expense.  
 The Newtonian approach is the least expensive method, as it simplifies a 
molecule by boiling its constituent atoms down to "balls", which are bound to other 
"balls" via "springs" (bonds). Electrons and their orbitals are not treated explicitly; rather, 
electronic effects are included in the "ball" concept via parameterization of specific, 
predetermined atom types in an empirical forcefield. These atom types are created 
according to the nature of chemical bonds between different elements as they are 
observed in vitro. Thus, the nature of the bond between elements incorporates the 
"electronic" aspect of the bonded atoms.  
 The equation describing the movement of these "balls on springs" is based on 
Newton's second law of motion: 
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Fi = miai = mir¨i         (3.1) 
 
Where Fi  is the force acting on particle i, mi is the mass of particle i, ai  is its acceleration, 
and r¨i  is the second derivative of the particle position with respect to time. Because Fi  is 
also dependent on the gradient of the potential energy function, Fi  can alternatively be 
expressed as: 
 
Fi = -!iU(r)          (3.2) 
 
Where U(r) is the potential energy function of particle i. 
 
 Although the accuracy of the simulation of electronic effects in molecular systems is 
limited by using a classical mechanical approach, it has been proven by countless 
molecular modeling studies spanning two decades to be effective in reproducing 
experimental phenomena and its shortcomings are known. 
 In purely Newtonian simulations the system exists in a vacuum, which makes for 
more simplistic--and hence faster--computing, but biomolecules in vitro/vivo generally 
exist in a solvated environment. Solvent effects can play a significant role in determining 
the motion of atoms in the biological system. These forces can be modeled using a 
Newtonian approach by solvating the system with explicit water molecules. However, 
explicit solvation drastically decreases computational affordability, and is not always 
practical, especially when much of the increase in computing is due to (and wasted on) 
water-water interactions. In an explicit model, the solvent molecules are independent 
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entities with their own force-variables, just as any atom in the biomolecule. By stripping 
these molecules of their individuality and reinterpreting them as an overall force, 
computational expense can be reduced to near- in vacuo conditions, yet solvent effects 
are still taken into account during the simulation. Thus, by representing solvation effects 
as a term within the mathematical definition of atomic motion of the biomolecule, one 
can include solvent effects on the system with reasonable accuracy, but without the 
expense of explicit solvent. This method, called stochastic dynamics, employs the 
Langevin equation (equation 1.3, below) to achieve that end: 
 
mir¨i = -!iU(r) - mi!ivi(t) + Ri(t)       (3.3) 
 
Where -!iU(r) is the gradient of the potential energy function, and incorporates classical 
mechanics (see equation 1.2), mi!ivi(t)  represents the drag force due to solvent-induced 
friction on particle i, and Ri(t) is a random force representing the probability of particle i 
colliding with solvent.  
 
 The third method of molecular dynamics is a composite of classical molecular 
mechanics coupled with a quantum mechanical approach (QM/MM). Unlike the 
stochastic method and Newtonian mechanics alone, the inclusion of quantum mechanics 
enables the algorithm to explicitly model electronic orbitals, greatly enhancing the 
accuracy of the simulation. This is achieved by employing the Schrödinger equation in 
the context of the overall energy of the system:  
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!eff!(r, Rq, Rc) = E(Rq, Rc)!(r, Rq, Rc)     (3.4) 
 
Where !eff is the effective Hamiltonian for the system, ! is the wave function for the 
system, r is the coordinates of the electrons, Rq is the coordinates of the QM nuclei, and 
Rc is the coordinates of atoms having solely molecular mechanics parameters. 
 An explicit-orbital model has the capacity to simulate not only the movement of 
particles in space, but can also simulate the formation/cleavage of bonds between atoms-- 
a faculty that the classical and stochastic methods do not possess. Despite its superiority 
to other methods of modeling, using an exclusively quantum approach when simulating 
systems larger than 300 atoms becomes prohibitively expensive owing to the complexity 
of the equation shown in equation 1.4. To circumvent this problem, large compounds 
(including most biomolecules) are often divided into a quantum mechanical segment and 
a Newtonian mechanical segment. For example, when modeling an enzyme the quantum 
mechanical region typically consists of the active site residues thought to be involved in 
metabolism, the substrate, cofactor, and heme. The remainder of the enzyme is simulated 
using a classical forcefield instead, as it has little or no impact on the reaction mechanism 
itself.  
 To further decrease the overall computational cost, each atom belonging to the 
quantum region is electronically defined using a semi-empirical method that calculates an 
atomic electron density function. Algorithms for this purpose include AM1, MNDO, and 
PM3. 
 Mitigating the costliness of the QM/MM approach via semi-empirical methods 
has been successful to some extent, however, modeling large systems -- and 
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metalloenzyme systems in particular-- remains difficult. It is becoming increasingly 
feasible, however, with recent developments improving processor speed, and a rising 
availability as computers containing such processors become more financially affordable.  
 Regardless which methods specified above is employed, molecular dynamics is a 
powerful tool in the field of computer aided drug development. Unlike most docking 
methods, molecular dynamics allows the movement of the receptor as well as the ligand, 
which increases the likelihood of the ligand finding the correct binding mode(s). In the 
same vein, interactions responsible for the binding modes may be revealed even down to 
the electronic level if quantum mechanics are employed. The major drawback regarding 
the use of MD as a drug developing tool is the very trait that makes it useful over other 
techniques: time. Because of the sheer number of calculations required to be solved for 
each atom in the system, and because these calculations must be repeated for each time-
step in the simulation, the real-time wait for MD results can be on the order of weeks to 
months. 
 
3.2. Materials and Methods 
 
3.2.1. Preliminary Structure Preparation  
 The effector, dapsone, was built with Sybyl (Tripos, St. Louis, MO) and energy 
minimized. Geometry optimization was performed at the AM1 level with Gaussian03 
(Gaussian, Inc., Wallingford, CT). The resulting charges were fitted to Amber force field 
parameters using the resp algorithm in Antechamber from the Amber8 suite of programs. 
Dapsone was subsequently placed into the active site of the X-ray crystal structure of 
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CYP2C9 12 using AutoDock3.0 79, 80 and oriented according to the model determined by 
NMR 38. Flurbiprofen, the substrate, had been co-crystallized with the enzyme and its 
coordinates were left undisturbed. Using Amber's XLEaP program, the system was then 
solvated with a pre-equilibrated TIP3P periodic box whose water molecules extended 
roughly 8 Å from the solute. Chloride counterions were also added to neutralize the net 
charge, also with XLEaP.  
  
3.2.2. Molecular Mechanics/Molecular Dynamics Simulation  
 On an SGI Fuel running Irix 6.5, the Sander module was used to minimize the 
energy of the solvated system, as well as to calculate all other molecular mechanics and 
molecular dynamics with the Cornell 94 81 force field. The system was kept at a constant 
pressure for 1000 steps of minimization using a 2 ps timestep to relax the system and 
relieve steric clashes between non-bonded atoms. Following this, a 3 ps molecular 
dynamics simulation was run to allow the water molecules to fill areas of vacuum around 
the solute and come to an equilibrium density. Non-bonded atomic interactions were 
limited by a 9 Å cutoff and 25 kcal/mol · Å of positional restraints were applied to the 
solute to hold it fixed in space. Gradually the positional restraints were removed during 
the next 600 steps of equilibration until the solute was free to move randomly. The final 
dynamics run heated the system from 100 K to 300 K over 20 ps. Finally, a production 
run during which the system was held at a constant temperature of 300 K was performed 
for a 4 ns duration. The changes in the energetics of the system during the dynamics 
simulations were monitored using the Carnal module of Amber.   
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3.2.3. Analysis of MD Simulation  
 The trajectory of the production run was analyzed in MOIL-View 82. Hydrogen 
bonding was determined by measuring the distance between the donor and acceptor 
atoms with a cutoff of 4.0 Å. Pi-stacking was determined by visual assessment of the 
geometry of the aromatic rings in relation to one another (i.e. sandwich stacked, T-
stacked) and by measuring the distance between the closest carbons using a cutoff of 5 Å 
74. 
 
3.3. Results and Discussion 
 Over the course of 4 ns, both H-bonding and pi-stacking appear to play important 
roles with regards to active site substrate positioning in the MD simulation of the 
dapsone-flurbiprofen-CYP2C9 system (Figure 3.1). For the first 1400 ps of the 
simulation the substrate is bound in the active site via H-bonding of its carboxylate group 
to the amine side chains of Arg-108 and Asn-204; the former is known via mutagenesis 
studies to be important in flurbiprofen metabolism by CYP2C9 16. Dapsone is also bound 
in the active site via H-bonds, which are formed between one of its sulfone oxygens and 
the amine side chain of Asn-474, and more transient H-bonds are formed via its amine 
hydrogens to the backbone carbonyl oxygen of Thr-301 and via its sulfone oxygens to the 
hydroxyl side chain of Ser-209 (Figure 3.2). These electrostatic interactions possibly 
play an important role in the functionality of dapsone as an effector, since the substitution 
of a sulfide for the sulfone group in compound 8 results in loss of activity as an effector 
of flurbiprofen metabolism by
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Figure 3.1.  Overlaid Distance Plots of Flurbiprofen 4’-H to the Heme Iron In the Presence of Dapsone , Dapsone to F476, and 
Dapsone to Flurbiprofen. 
Overlaid distance plots of flurbiprofen 4’-H to the heme, dapsone to F476, and dapsone to flurbiprofen are shown. 
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Figure 3.2. H-bonds Formed During MD Between Dapsone and Active Site  
Residues of CYP2C9 in the Presence of Flurbiprofen. 
H-bonds formed between dapsone and active site residues during the MD simulation in 
the presence of flurbiprofen are illustrated. Dapsone is tangerine, flurbiprofen is forest, 
active site residues are royal blue, and the heme is crimson. H-bonds are denoted as black 
dotted lines and are measured in Ångstroms. 
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CYP2C9, and substitution of the sulfoxide with another H-bond accepting group like the 
sulfoxide in compounds 9 and 14 retains the activity of these compounds. Dapsone also 
formed the occasional H-bond with the carboxylate moiety of flurbiprofen, though these
interactions were relatively weak, hovering around 4 Å and forming only in 370 frames 
out of the 4000 frame trajectory. In addition to forming electrostatic interactions, dapsone 
also appeared to pi-stack with Phe-476 as well as with flurbiprofen.  
 From 0 to 1300 ps the average distance between Ring 1 of dapsone and Ring 1 of 
flurbiprofen was 3.99 Å, which is well within the bounds of the cutoff for pi-stacking 
interactions. However, the average distance between the substrate 4'-H, where oxidation 
occurs, and the heme iron was 6.12 Å, which made metabolism highly unlikely to occur. 
Though both rings of flurbiprofen interacted with both rings of dapsone, Ring 2 of the 
effector did not associate with flurbiprofen as often as Ring 1, which stacked with one 
ring or another of the substrate in various dimer-like geometries and often with both 
substrate rings in a trimer-like geometry (Figure 3.3). Ring 1 of dapsone also appeared to 
trimerize with Phe-476 and Ring 1 of flurbiprofen, though at different intervals during the 
course of the trajectory dapsone favored association with one over the other. Up until the 
1300 ps mark the average distance between Ring 1 of dapsone and the phenyl side chain 
of Phe-476 was 5.96 Å, but at 1300 ps they began to associate more closely, maintaining 
a distance between 3.5 Å and 5 Å until 2800 ps. This action resulted in the effector 
distancing itself from the substrate by an average of 6.15 Å over the course of the 
trajectory from 1300 ps to 2800 ps, and spans a range of distances from about 4 Å to 8.5 
Å, which is also shown in the graph in Figure 3.1.  
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Figure 3.3. Pi-Stacking Interactions Between Dapsone, Phe-476 And Flurbiprofen in 
the Active Site of CYP2C9 During MD. 
Pi-stacking interactions formed during the MD simulation between dapsone, Phe-476 and 
flurbiprofen in the active site of CYP2C9 are illustrated. Dapsone is colored tangerine, 
flurbiprofen is forest, active site residues are royal blue, and the heme is crimson. Pi-
stacking interactions are denoted by black dotted lines. 
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 Concurrently, the distance between the heme iron and the 4'-H of flurbiprofen 
shortened by 1 Å, to 5.12 Å, which is in agreement with experimental data obtained from 
NMR studies that showed the Fe-4'-H distance decreased by 0.9 Å in the presence of 
dapsone. At times the Fe-4'-H distance reached numbers as low as 3.27 Å (Figure 3.4).  
 Interestingly, at 1400 ps the H-bond between the carboxylate moiety of 
flurbiprofen and Arg-108 dissolved as the substrate moved closer toward the heme iron, 
though the substrate was able to maintain H-bonds with Asn-204 throughout the 1400-
1800 ps time frame. H-bonding between Arg-108 and the substrate still occurred 
frequently, but were not constantly sustained. At 2800 ps Ring 1 of dapsone once again 
came into close proximity of Ring 1 of flurbiprofen and from this point to the end of the 4 
ns trajectory the average distance between them was 3.92 Å, indicating a tighter 
interaction between the two compounds. During this same span of time, dapsone was also 
able to stack with Phe-476 and in doing so pulled flurbiprofen away from the heme to the 
point that it was no longer in position to be metabolized. It was at this point that the H-
bond between the side chain of Arg-108 and the carboxylate group of the substrate re-
solidified. 
The fact that a shorter distance between flurbiprofen and dapsone corresponded to a 
larger distance between the 4'-H and the heme iron gives the appearance that dapsone 
should in fact be an inhibitor of flurbiprofen metabolism by CYP2C9. However, this is 
not supported experimentally. It may be that dapsone does actually pull flurbiprofen 
away from the heme iron, but only when the two compounds form very close 
interactions. Aromatic active site residues like Phe-476 may, by stacking with the 
effector, draw away from the substrate at times so that an optimum distance between 
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Figure 3.4. Pi-Interactions Formed by Dapsone, Phe-476 and Flurbiprofen When 
the Substrate 4’-H-Fe Distance Is at Its Shortest During MD. 
Pi-interactions formed by dapsone, flurbiprofen, and Phe-476 in the active site of 
CYP2C9 when the  distance of  the 4’-H of flurbiprofen to the heme iron is at its shortest 
are shown. Dapsone is colored tangerine, flurbiprofen is forest, active site residues are in 
blue, and the heme is green. Pi-stacking interactions and the 4’-H-Fe distance 
measurement are shown as dotted lines with measurements in Ångstroms.  
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dapsone and flurbiprofen is reached and metabolism can occur. At weaker interactions 
dapsone may stabilize the substrate in a position favorable to metabolite formation. It 
must be remembered that binding is a dynamic process and as such, the "closely stacked" 
and "moderately stacked" states of the flurbiprofen-dapsone complex exist in 
equilibrium, with the "moderately stacked" state predominating. This is consistent with 
QM/MM data discussed later in Chapter IV and with docking results obtained from 
eHiTS in Chapter V.  
 In contrast to the dapsone-flurbiprofen-enzyme complex, the MD simulation 
consisting of flurbiprofen alone in the active site of CYP2C9 did not show fluctuations in 
distance between the heme iron and the 4'-H of the substrate (Figure 3.5). In fact, the 
distance between these two atoms averaged 5.01 Å, which is a slightly shorter distance 
than that averaged by flurbiprofen in the presence of dapsone.  In addition, the shortest 
distance between the 4’-H of the substrate and the heme iron (3.18 Å) was slightly shorter 
than that achieved by the 4’-H in the presence of dapsone. However, this does not mean 
that dapsone plays no role in the activation of flurbiprofen 4’-hydroxylation by CYP2C9. 
Rather, it could indicate that a longer MD simulation might be necessary to fully gain 
perspective on the behavior of flurbiprofen in the active site of CYP2C9 with and without 
dapsone present and the 4 ns time scale analyzed here may be insufficient to observe 
relevant interactions and substrate behaviors. Also, waters were excluded from the active 
site itself (though they were explicitly included externally as solvent). Active site waters 
are known to play a role in the catalytic P450 cycle, and the lack of them here may affect 
the behavior of flurbiprofen in these simulations. Another factor that could affect the 
outcome of the MD results is the use of a ferric heme  
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Figure 3.5. Distance Plot of Flurbiprofen 4’-H to the Heme Iron in the Absence of Dapsone. 
The distance of the 4’-H of flurbiprofen to the heme iron over the course of the 4 ns MD simulation of CYP2C9-flurbiprofen with 
dapsone absent from the active site is illustrated. 
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iron. The most reactive species in the catalytic cycle is the Fe
IV
 oxoheme 
3
, whose 
presence may cause the substrate to exhibit more accurate binding behavior. Overall, 
however, the MD simulation itself of the  CYP2C9C-flurbiprofen-dapsone complex did 
illuminate  
aspects of possible mechanisms of activation and were in agreement with both external 
experimental data and computational data obtained using other methods in this work. 
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CHAPTER IV 
Determination of Effector-Active Site Binding in 
CYP2C9 with AutoDock3.0 
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4.1. Introduction 
 
As of the writing of this work, many prefer AutoDock for ligand-receptor docking due to 
its reliability and its relatively low cost 
83-86
. The AutoDock distribution is actually a suite 
of programs composed of three complementary units: AutoTors, AutoGrid, and 
AutoDock. An optional GUI interface called AutoDockTools is available separately. 
Each of these is described in further detail below. 
 AutoTors is a program responsible for defining the flexibility of the ligand. First, 
the ligand is divided based on bond torsion into rotatable "branches" that radiate from a 
fixed portion of the compound, the "root." Branches can be nested within one another, in 
which case they are numbered in order from the outermost bond to the root. It is 
generally assumed that all rotatable bonds will be allowed to move during the docking 
process, as this most closely mimics compounds in reality, but constraints can be applied 
to otherwise moveable bonds if the user so chooses. During the docking process, any 
confomer state that violates such a constraint will be immediately rejected. One instance 
in which constraints would be needed, however, is in the case of a large ligand that 
exceeds the maximum moveable torsions allowed by the docking algorithm. This limit 
can be raised by altering the appropriate header file for the docking program, but a 
greater number of allowed torsions brings with it a higher computational expenditure. In 
that regard it may be more economical to apply constraints, although thoughtfully so as to 
disrupt the natural flexibility of the ligand as little as possible. The output file from 
AutoTors is then used as the input file for the actual docking process. The program is not 
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applied to the receptor, as the receptor is held fixed during docking. 
 AutoGrid is another preparatory program, but applied exclusively to the receptor 
(also referred to as the "macromolecule"). As with most docking programs, the receptor is 
held fixed in space in the interest of conserving computational expense. AutoGrid 
calculates all potential energy interactions between the atom types present in a specified 
ligand and those in the macromolecule into atom-specific "map files" by referencing a 
comprehensive database included with the AutoDock suite. This database is composed of 
van der Waals radii for most atoms in the periodic table, several hundred possible atom-
to-atom Leonard-Jones 12-6 potentials, and coefficients peculiar to AutoGrid's energy-
calculating algorithm.  
 In the process of generating the grid maps, the program repeatedly surveys the 
active site topology and plots these potential interaction energies at finite grid points 
using a probe atom. The atom types present in the ligand dictate the chemical identity of 
the probe atom, whose chemical properties change depending on which atom type in the 
ligand it is representing. In addition to van der Waals interaction energies, electrostatic 
potential grid maps are also generated; the probe "atom" in this case, however, is actually 
a charge-- e , +1.60219x10-19 C. The spacing of the grid matrix is set by default to 0.375 
Ångstroms, which, at roughly one-fourth the length of a carbon-carbon single bond, is 
fine enough to provide detailed interatomic information while limiting needless 
calculations. However, the grid point spacing can be made smaller by the user to achieve 
a higher resolution, or be made greater to reduce further computational cost. The grid 
boundaries are arbitrarily set by the user, requiring some knowledge of active site 
residues instrumental in ligand-receptor interaction, or at least the general location of the 
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binding site. While there is no limit concerning the dimensions of the grid box, a larger 
box volume will naturally hold a greater number of possible interaction energies, which 
results in a higher computing cost. By creating topological energy grid maps tailored for 
only the atom types present in a specific ligand, and also by delimiting docking site 
boundaries via its grid box, AutoGrid increases the overall efficiency of the docking 
process. 
 AutoDock, the namesake of the program suite, actually executes the docking 
algorithm. There are three main algorithms users can implement in a docking run: Monte 
Carlo simulated annealing, a genetic algorithm, and a Lamarckian local search algorithm 
used in conjunction with the genetic algorithm.  
 In simulated annealing, a ligand randomly orients and re-orients itself as it 
samples the conformational space determined by the binding site of a fixed receptor. At 
each step a small random change is applied to each degree of freedom present in the 
ligand, including three-dimensional spatial translation and rotation of flexible bonds that 
alter dihedral angles. The energy of the resulting new ligand configuration is interpolated 
from the pre-calculated energy potential grid calculated by AutoGrid. If the new energy is 
more negative than that of the conformation in the previous step (and therefore more 
stable and likely to occur in vitro), then the new configuration is accepted and the process 
repeats itself to form a new random confomer. If the energy is more positive, however, it 
undergoes a temperature-dependent probability test to determine the likelihood of the 
confomer's in vitro existence at the user-defined temperature, T. The expression 
describing this probability is given in equation 4.1: 
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P(!E) = e [!E/(kBT)]        (4.1) 
 
where delta E is the energy difference between the original ligand configuration and the 
new one, and kB is the Boltzmann constant. The higher the temperature, the greater the 
probability of acceptance of  higher-energy structures. Likewise, at lower temperatures 
the docking algorithm becomes more "stringent," rejecting a greater number of high-
energy confomers.  
 The simulation is initiated at a high temperature, which provides the energy 
required to dislodge confomer atoms from their local minima. It is critical that the initial 
temperature be low enough that it is not too energetically permissive, but not so low that 
the ligand becomes trapped in a local minimum. The temperature is then lowered slowly, 
allowing new confomers a greater chance of settling into a new minimum with a lower 
internal energy than their immediate predecessors. The simulation proceeds in multi-step 
consecutive cycles, each conducted at a specific temperature and each lower in 
temperature than the last. A new cycle is initiated and the old one terminated after a set 
number of steps, and the cyclic schedule is determined by equation 4.2: 
 
Ti = gTi -1          (4.2) 
 
where Ti is the temperature at cycle i, and g is a constant between zero and one. The 
process repeats until the user-defined total number of cycles has been reached. The result 
is the lowest-energy confomer of the ligand attainable by the algorithm in the allotted 
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number of cycles. If multiple confomers are desired for comparison, then the algorithm 
runs N number of "copies" of each temperature cycle to produce N number of resulting 
ligand confomers. Each copy runs independently of the others, resulting in configurations 
that are unrelated to and unbiased by one another.  
 While used extensively for ligand-receptor docking, the simulated annealing 
algorithm has its drawbacks. For one, it can be very slow, particularly in such cases when 
the receptor site is large, thus increasing the amount of conformational space to sample, 
or when docking a complex ligand containing many degrees of freedom. In addition, the 
reliability of the algorithm depends largely on its ability to find the global energy 
minimum for any given ligand, which requires fine-tuning of the temperature range in 
which the algorithm is run. Such refinement can be a lengthy and tedious task to 
implement. In such cases alternative algorithms are more efficient. 
 AutoDock is capable of conducting simulated annealing, however, it can 
alternatively employ a type of genetic algorithm peculiar to the program. This docking 
method employs a 2-point crossover and random mutation. An optional feature used in 
conjunction with the default genetic algorithm is a local searcher based on Solis' and 
Wets' optimization algorithm 
87
, which increases the precision of docking results, in that 
the binding mode corresponds to experimentally determined metabolite formation. In 
defiance of Mendelian genetics, the local searcher alters the phenotype, which results in a 
modification of the genotype. Because this approach to mutation entails adapting an 
individual to its environment and subsequently passing that new trait to its offspring, this 
algorithm is termed the "Lamarckian genetic algorithm." The Solis and Wets approach to 
conformational searching involves the determination of the probability of a given 
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confomer to change translationally or rotationally to a particular state. This variance is 1 
for every initial confomer in the population, and is either doubled or halved depending on 
the number of consecutive free energy drops (successful mutations), or free energy jumps 
(failed mutations). AutoDock can use the classical Solis and Wets method described 
above, or implement a so-called "pseudo Solis and Wets" method, in which the variances 
are scaled to account for their relative magnitudes. In this study we employed the latter. 
 Regardless of the algorithm used to dock the ligand to the receptor binding site, a 
scoring function is required to rank the resulting confomers. AutoDock uses scoring 
function based on the principle of the hydrophobic effect. When ligand and receptor are 
separate from each other and both fully solvated, water molecules tend to organize 
around them by H-bonding with other water molecules and also with any H-bond 
donating or accepting functional groups present at the solute interfaces. When the ligand 
binds to the receptor, the waters once lining the binding site and also those surrounding 
the ligand are displaced into the bulk solvent, reducing the overall stabilizing effect of 
water-solute H-bond formation. AutoDock uses these solvent changes in entropy to 
estimate the binding energy of the ligand to the receptor, even though docking runs are, 
for the sake of computational economy, conducted in vacuo. This is possible due to 
Hess's law of heat summation, which states that the change in free energy between two 
states will be the same, regardless of the way in which those states were achieved. 
Therefore equation 4.3 can be used to calculate the binding of a given ligand, L, to a 
receptor, R, in solvation: 
 
Gbinding,solution = Gbinding,vacuo + Gsolvation(LR) - Gsolvation(L+R)           (4.3) 
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Data obtained from the docking simulation itself is used to calculate Gbinding,vacuo, and 
Gsolvation(LI) and Gsolvation(E+I) can be estimated by calculating the surface area of each atom 
isolated from solvent upon ligand-receptor complex formation and weighting that surface 
area with an atom-specific solvation parameter. Other energetic components are also 
taken into account and incorporated into the scoring function, such as loss of degrees of 
freedom of the ligand upon binding to the receptor, and classical molecular mechanics 
energy functions such as electrostatic, van der Waals, and H-bonding. Scores are in units 
of kcal/mol.  
 After a docking run is completed and the resulting confomers scored, confomers 
can be clustered according to RMSd (the cutoff for which is by default 0.5 Å but can be 
changed to suit the needs of the user). Confomers in the same cluster also tend to score 
within a small range of energy on the order of tenths of a kcal/mol. When clusters are  
plotted with the number of confomers per cluster as a function of energy (i.e. score), the 
resulting histogram provides a clear survey of the distribution of the results.  
 
4.2. Materials and Methods  
  
4.2.1. Preliminary structure preparation and MD simulation 
 Dapsone and 19 dapsone analogs consisting of the compounds listed in Table 4.1  
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Table 4.1. Structures of Dapsone and Dapsone Analog Effectors. 
 
 Type X Y Z Name % Change in 
Flurbiprofen 4!-
Hydroxylation 
(observed) 
1 1 4,6-CH3-C4HN2-2-NH- -NH2 - Sulfamethazine -18.82 
2 1 H2N- -NH2 - Sulfanilamide -17.84 
3 1 C4HN2-NH- -NH2 - Sulfadiazine -17.05 
4 1 2-CH3-C3NO-4-NH- -NH2 - Sulfamethoxazole -17.05 
5 1 4-NO2-C6H4- -NH2 - 4-(4-
nitrophenylsulfonyl)aniline 
-10.58 
6 3 - - - Dibenzothiophene -10.58 
7 2 C6H5 -H NH Diphenylsulfimine -1.18 
8 2 C6H5 -H - Diphenylsulfide 1.18 
9 2 C6H5 -H O Diphenylsulfoxide 3.53 
10 1 C6H5-NH- -H - Diphenylsulfone 39.98 
11 1 4-CH3-C6H4-NH- -CH3 - Di-para-tolylsulfone 50.57 
12 1 4-NH2-C6H4- -NH2 - Dapsone 64.09 
13 1 4-CH3O-C6H4- -OCH3 - 4,4!-Dimethoxyphenylsulfone -25.0 
14 2 4-CH3CONH- C6H4- -NHCOCH3 O 4,4!-
Diacetamidophenylsulfoxide 
5.03* 
15 1 4-HOOC-C6H4- -COOH - 4,4!-Dicarboxyphenylsulfone -5.0 
16 3   - Dibenzothiophenesulfone 17.82* 
17 1 4-HO-C6H4- OCH3 O 4-Hydroxyphenyl-4!-
methoxyphenylsulfone 
17.92* 
18 1 4-CH3CONH- C6H4- -NHCOCH3 - 4,4!-
Diacetamidophenylsulfone 
8 
19 1 4-HO-C6H4- -OH - 4,4!-dihydroxyphenylsulfone 95 
20 1 4-CH3O-C6H4- -H - 4-Methoxyphenylsulfone 44.84* 
 
*non-experimental CoMFA-predicted values (model R
2
 = 0.80) . 
 
 
Structures of dapsone and the 19 dapsone analogs comprising the training set are shown. 
Negative numbers indicate inhibition of flurbiprofen 4’-hyrdoxylation, whereas positive 
numbers indicate activation [J.S. Aguilar, unpublished results]. 
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were built with Sybyl (Tripos, St. Louis, MO) and energy minimized. Geometry 
optimization was performed at the AM1 level with Gaussian 03 (Gaussian, Inc., 
Wallingford, CT). The effector, dapsone, was oriented in the active site of the X-ray 
crystal structure of CYP2C9 
12
 according to the model determined by NMR 
38
. 
Hexacoordinate heme parameters were obtained from the AMBER parameter database 
maintained by Richard Bryce at the University of Manchester 
(http://pharmacy.man.ac.uk/amber/cof/heme_all_inf.html) 
88
. Flurbiprofen, the substrate, 
had been co-crystallized with the enzyme. The flurbiprofen-dapsone-CYP2C9 complex 
was prepared for molecular dynamics using the Amber suite of programs and simulation 
were performed, both according to the protocol described in Chapter III Materials and 
Methods. Dapsone, or dapsone plus flurbiprofen were extracted from the resulting 
structure creating the active site used by the docking software. All dapsone analogs were 
docked into two active site structures: one with flurbiprofen present, and one without. 
Because in vitro NMR and metabolite data were known for dapsone and flurbiprofen 
34
, 
these two compounds were docked first, before docking the dapsone analogs, to ensure 
the quality of the model's parameterization; the model was considered poor and would 
require re-parameterization if the resulting docked poses of dapsone and flurbiprofen 
failed to conform to the poses established in vitro. 
  
4.2.2. AutoDock Screening   
 The enzyme was imported into the GUI interface AutoDockTools, and an Amber-
derived force field was applied. Non-polar hydrogens were merged, but polar hydrogens 
were allowed to remain explicit. Kollman united atom charges were then calculated and 
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added to the protein. Minimized dapsone analogs were also imported into 
AutoDockTools, merging non-polar hydrogens, and assigning Gasteiger charges for each 
compound. Compounds containing acidic functional groups were protonated or 
deprotonated depending on their respective pKa values and a pH of 7.4. The active site 
boundaries for grid point calculations were defined by a 40  Å3 box centered on the 
fluorine of flurbiprofen (or on the corresponding coordinates for the empty enzyme). 
Dapsone and 19  dapsone analog effectors that had been used as a test set in a previous 
CoMFA analysis [J.S. Aguilar, unpublished results] (Table 4.1) were then docked into 
the active site of CYP2C9-flurbiprofen or CYP2C9 alone using a genetic algorithm. 
Flurbiprofen itself was also docked into the empty active site of CYP2C9. The resulting 
50 docked conformations were scored using AutoDock's native scoring function and 
based on the lowest docking energy. Docking energy is defined as the sum of the final 
intermolecular energy and the final internal energy of the effector of each docked 
conformation of every effector.  
  
4.2.3. In Silico- In Vitro/CoMFA-Predicted Data Correlation Evaluation  
 The correlation coefficient of determination relating the in vitro effector-mediated 
change in flurbiprofen metabolism and the docking results was calculated using 
Microsoft Excel. The r-squared value was calculated using three sets of data:  1) the 
lowest docking energy for each effector docked in the presence of flurbiprofen; 2) by the 
docking energy of the binding mode, where the greatest number of docked poses with an 
interconfomer RMSd of 0.5 Å or less was judged to be either "productive" (i.e. causing 
activation) or "nonproductive". An effector was considered to be productive if it formed 
 84 
favorable nonbonded interactions with flurbiprofen, which had been crystallized in an 
orientation that promoted 4'-hydroxyflurbiprofen formation. Favorable interactions were 
determined in part by the pharmacophore produced by an earlier CoMFA [J.S. Aguilar, 
unpublished results], and included H-bonding (determined by a distance cutoff of 4.0 Å 
between donor and acceptor atoms), and pi-interactions (determined by a distance cutoff 
of 5 Å between aromatic ring carbons 74); 3) a tally of the number of confomers 
comprising the binding mode was taken for each effector, and correlation coefficients 
(R2) were calculated from both the number of confomers comprising the mode and the 
score corresponding to it. If the results for a particular effector were bimodal, the lowest 
energy mode was chosen for analysis. 
  
4.2.4. Quantum Mechanical Analysis of Docked Effector-Substrate Interaction Energy    
 Flurbiprofen along with the binding mode of seven docked effectors were cut 
from the ligand-receptor complexes. Using HyperChem (Hypercube, Inc., Gainsville, FL) 
at the PM3 level of theory, energies of the substrate and effectors were calculated, as well 
as the substrate-effector complexes. This protocol served to determine whether the 
effector and/or substrate was in a more energetically favorable state alone or complexed 
with one another.  
  
4.2.5. Visual Analysis  
 Interatomic measurement was conducted in PyMol (DeLano Scientific, Palo Alto, 
CA). Visualization of the results was performed in PyMol and AutoDockTools3.0.  
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4.3.  Results and Discussion 
 In the initial docking runs, the heme iron was parameterized with the VDW term 
and Lennard-Jones potentials multiplied by a large scaling coefficient. Under these 
conditions, and in the absence of flurbiprofen, dapsone preferred to dock in a 
nonproductive conformation with sulfone oxygens pointing toward the heme iron (Figure 
4.1). Flurbiprofen, when docked into the empty active site assumed a pose in which its 
carboxylate group associated closely to the heme iron; as in the case with dapsone, this 
conformation could not result in metabolism to the known metabolite (Figure 4.2). 
Knowing that the heme iron may be attracting highly electron-dense groups on the 
ligands via electrostatic effects, compounds 19 (formal charge -1) (Figure 4.3) and 15 
(formal charge -2) (Figure 4.4) were docked in the empty active site to observe their 
conformations. In keeping with results seen with dapsone and flurbiprofen, the 
deprotonated oxygens of these two compounds oriented their negatively charged oxygens 
toward the heme iron. Interestingly, the docking energy of 15 was nearly an order of 
magnitude lower than that of 19. The reason for this phenomenon is not known. 
Compound 15, on the other hand, is a dianion and could form favorable H-bonding with 
Arg-108, thus driving the docking energy lower. This is not a likely scenario, however, 
due to the close proximity of the effector carboxylate group with that of flurbiprofen, 
which is energetically unfavorable. Because dapsone docked in a conformation that 
conflicted with previously published work 
12
, and because the docking energy of 15 was 
so extreme compared to similarly-structured 19, it was decided to first dock these three 
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compounds in CYP2C9 in the presence of flurbiprofen for comparison before docking 
additional dapsone analogs in the empty active site. 
 
 
 
Figure 4.1. Initial Docking of Dapsone into CYP2C9 Empty Active Site by 
AutoDock. 
Initial docking results of dapsone into the empty active site of CYP2C9 by AutoDock are 
shown. Active site residues are shown in royal blue, dapsone is periwinkle, and the heme 
is crimson. 
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Figure 4.2. Initial Docking of Flurbiprofen into CYP2C9 Empty Active Site by 
AutoDock. 
Initial docking results of flurbiprofen into the active site of CYCP2C9 by AutoDock are 
illustrated. Active site residues are royal blue, flurbiprofen is periwinkle and the heme is 
crimson. 
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Figure 4.3. Initial Docking of compound 19 into CYP2C9 Empty Active Site by 
AutoDock. 
Initial docking results of 19  into the empty active site of CYP2C9 as calculated by 
AutoDock are illustrated. The lowest energy confomer is displayed in yellow, the mode is 
magenta, active site residues are royal blue, and the heme is crimson. 
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Figure 4.4. Initial Docking of Compound 15 into CYP2C9 Empty Active Site by 
AutoDock. 
Initial docking results of 15  into the empty active site of CYP2C9 as calculated by 
AutoDock are illustrated. The lowest energy confomer is shown in yellow, the mode is 
magenta, active site residues are royal blue, and the heme is crimson. 
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 When dapsone docked into the active site in the presence of flurbiprofen (Figure 
4.5), the simultaneous presence of substrate in the active site largely mitigated this 
phenomenon. The same effect of flurbiprofen on the docking of dapsone applied to 
compounds 15 (Figure 4.6) and 19 (Figure 4.7). However, it is inconclusive as to 
whether this was due to some stabilizing interaction such as pi-stacking between effector 
and flurbiprofen (though in the case of 19 distances of less than 5 A between their 
respective ring carbons do suggest this), or the substrate shielding the iron's charge, or 
more a matter of steric hindrance. Also possible are effector-active site interactions, such 
as stacking of both 19 and 15 with Phe-476 and H-bond formation between the sulfone 
oxygens of 15 to the amino side chain of Asn-474. The docking of dapsone produced two 
confomers: a lowest energy confomer and a mode confomer, unlike compounds 15 and 
19. The lowest energy confomer appeared to form stabilizing interactions with 
flurbiprofen in the way of pi-stacking, whereas the mode confomer formed interactions 
between active site residues: pi-stacking with Phe-476 and H-bonding with the side chain 
of Asn-474. The mode confomer does, however, form one interaction with the substrate 
by H-bonding to the carboxylate moiety via its amine group. 
 These questions were not pursued, since soon thereafter the error in the 
parameterization of the heme iron was identified. The VDW and Lennard-Jones values 
that had been miscalculated in the initial docking runs described above were re-calculated 
using the correct scaling coefficient, and in subsequent dockings into the empty enzyme 
dapsone bound in a conformation conducive to 4'-hydroxy metabolite formation (Figure 
4.8). In this pose the lowest energy confomer differed very little from the that of the 
mode (RMSd = 1.27 Å) and the sulfone oxygens pointed away from the heme. Since this  
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Figure 4.5. Initial Docking of Dapsone in CYP2C9 in the Presence of Flurbiprofen by 
AutoDock. 
Initial docking of dapsone in the active site of CYP2C9 simultaneously occupied by 
flurbiprofen is shown. Pi-stacking (a) and H-bonding (b) interactions are denoted by 
dotted lines. Distances of H-bonds are in Ångstroms. The lowest energy confomer is 
shown in yellow, the mode is magenta, flurbiprofen is forest, active site residues are royal 
blue, and the heme is crimson. 
A 
B 
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Figure 4.6. Initial Docking of Compound 15 in CYP2C9 in the Presence of 
Flurbiprofen by AutoDock. 
Initial docking of 15 into the active site of CYP2C9 in the presence of flurbiprofen is 
illustrated. Compound 15 is colored periwinkle, active site residues are royal blue, 
flurbiprofen is forest, and the heme is crimson. Pi-stacking and H-bonding interactions are 
shown as dotted lines. Distances of H-bonds are in Ångstroms. 
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Figure 4.7. Initial Docking of Compound 19 into CYP2C9 Active Site in the Presence 
of Flurbiprofen by AutoDock. 
Compound 19 initially docked into the active site of CYP2C9 in the presence of 
flurbiprofen is shown. Compound 19 is colored periwinkle, active site residues are royal 
blue, flurbiprofen is forest, and the heme is crimson.  Pi-stacking interactions are denoted 
as dotted lines. 
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Figure 4.8. Dapsone Docked into the Empty Active Site of CYP2C9 by AutoDock 
Using Recalculated van der Waals and Lennard-Jones Parameters.  
The docked conformation of dapsone in the empty active site of CYP2C9 using AutoDock 
with recalculated van der Waals and Lennard-Jones parameters is illustrated. Dapsone is 
shown in periwinkle, active site residues are royal blue, and the heme is crimson. 
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conformation orients the compound in such a way as to favor its catalysis by CYP2C9 to 
the primary metabolite, N-hydroxydapsone, the "sulfone up" pose is considered to be the 
"correct" orientation of dapsone within the CYP2C9 active site. 
 After correcting the scaling coefficient, flurbiprofen was also docked into the 
empty active site of CYP2C9 (Figure 4.9). Interestingly, its carboxylate moiety preferred 
to associate via hydrogen bonds to the side chain amino group of Asn-474 rather than 
Arg-108-- a residue to which binding is thought to be critical for flurbiprofen metabolism 
to occur. In this binding orientation, the distance between flurbiprofen's carboxylate 
group and the closest amine group of Arg-108 was 11.52 Å. Because the 4'-hydrogen was 
located 4.67 Å away from the heme iron, this was considered a nonproductive pose. 
These results suggest that the nonproductive binding mode is dominant over the 
productive one, however, it does not indicate that metabolism does not occur at all, or 
even that it occurs rarely. It possibly indicated that overall flurbiprofen metabolism may 
not be as efficient as it could be, but before that conclusion can be made one must take 
into account the fact that many factors contribute to metabolic efficiency that were not 
included in this model, such as the role of active site waters and reductase-enzyme 
electron transport. 
 Docking energies of dapsone and its analogs were fitted to a linear function to 
ascertain the degree of correlation between AutoDock's scores and the in vitro/CoMFA-
predicted percent change in flurbiprofen metabolism. The result was that no correlation 
could be found between the docking energies of the dapsone analog effectors and the 
actual effector-mediated change in flurbiprofen catalysis as determined by the model 
containing the corrected heme parameters (R2 = 0.009). However, based on the docked  
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Figure 4.9. Flurbiprofen Docked into the Empty Active Site of CYP2C9 by 
AutoDock Using Recalculated van der Waals and Lennard-Jones Parameters. 
Results of the docking of flurbiprofen into the empty active site of CYP2C9 by AutoDock 
using recalculated van der Waals and Lennard-Jones parameters are displayed. The lowest 
energy confomer is shown in yellow, the mode is magenta, active site residues are royal 
blue, and the heme is crimson. H-bonding interactions are shown for the mode only for 
clarity, and are denoted by dotted lines. Distances are in Ångstroms. 
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poses assumed by the dapsone effectors described above, it was postulated that the lack 
of in-vitro correlation with the docking energies may be due more in part to some 
parameterization error in the enzyme, rather than some inherent flaw in the program 
itself. Of particular concern was the heme, whose Fe+3 moiety is notoriously difficult to 
parameterize correctly using classical mechanical forcefields. Even after the VDW and 
Lennard-Jones terms were recalculated, it was discovered that AutoDock had not 
assigned solvation parameters nor partial atomic charges to any atoms in the heme 
moiety. Partial charges were included in the heme parameter files obtained from the 
AMBER parameter database, but were being overwritten by AutoDockTools in the 
course of pre-docking file preparation. A more recent set of heme forcefield parameters 
containing partial atomic charges differing from those used previously were applied 
89
 
and solvation parameters were added to the receptor file manually by atom type. 
Afterward, the entire ligand set was re-docked using the same methods described above. 
The resulting poses found for flurbiprofen (Figure 4.10) and dapsone (Figure 4.11) were 
similar to those seen in the system without heme solvation parameters and partial 
charges. Despite the implementation of these new parameters, no correlation could be 
determined from the new docking results, using either the lowest scoring confomer of 
each effector (R2 = 0.03) or the score corresponding to the mode (R2 = 0.01), or using the 
mode confomer tally (R2 = 0.03)  
 The difficulty in applying correct force field parameters to transition metals is 
ubiquitous in the field of molecular modeling. Our model may have been especially 
difficult to correctly assign hexacoordinate parameters to; given that docking different 
effectors may have displaced active site waters in different ways, those waters were  
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Figure 4.10. Flurbiprofen Docked into the Empty Active Site of CYP2C9 by 
AutoDock Using Re-assigned Heme Partial Charges. 
The docked confomer of flurbiprofen as calculated by AutoDock after re-assigning partial 
charges to the heme is shown. Flurbiprofen is colored periwinkle, active site residues are 
royal blue, and the heme is crimson. H-bonding interactions are displayed as dotted lines, 
with distances in Ångstroms. 
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Figure 4.11. Dapsone Docked into the Empty Active Site of CYP2C9 by AutoDock 
Using Re-assigned Heme Partial Charges. 
The docked confomer of dapsone as calculated by AutoDock after re-assigning partial 
charges to the heme is shown. Dapsone is colored periwinkle, active site residues are royal 
blue, and the heme is crimson. 
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removed from the active site to maintain consistency in docking. Among these was 
WAT600, which was the sixth ligand coordinated to the heme iron in the original 1R9O 
crystal structure. 
 Also adding to the difficulty in acquiring a solid in silico-in vitro/CoMFA-
predicted correlation is the fact that the binding mode can be interpreted in two different 
ways. There is the option of perceiving the RMS cluster histogram as a distribution of 
equally viable poses, or as a kind of confidence test in which the mode is the 
conformation most likely to exist in vitro, and confomers in smaller clusters therefore 
deemed less likely to exist. If the results are taken as a survey of all possible confomers, 
then all RMSd-derived clusters with all of their respective confomers would need to be 
analyzed. This approach was not taken here, due to the precedence set in the literature 
12, 
86, 90-92
 to draw analysis from only the binding mode and/or the lowest scored confomer in 
the case of bimodality. 
  Scoring functions are difficult to implement successfully, and it has been shown 
91, 92
 that binding modes are more indicative of the true binding orientation even though 
the binding mode often does not have the lowest docking energy in a given run. 
Therefore, in addition to data calculated by and obtained from AutoDock itself, docked 
effector binding mode-CYP2C9 complexes were subjected to semi-empirical QM 
analysis as a way to determine the accuracy of the docked results while bypassing 
AutoDock's scoring function. PM3 level of theory allows for a more explicit evaluation 
of electronic effects such as pi-stacking, which were of particular interest in the case of 
flurbiprofen-effector interactions given the presence and orientation of aromatic ring 
systems. Of the seven effectors chosen for analysis, five yielded a linear regression 
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correlation coefficient of 0.96 (Figure 4.12). Because the effectors were docked into a 
receptor in which flurbiprofen assumed a pose conducive to metabolism, any factor 
involved in orienting the effector in the active site is therefore also involved in 
heteroactivation. Between the PM3 data and visual assessment of ring orientation, the 
four activators lying along the trendline likely stabilize the substrate into a productive 
position via pi-stacking. One effector, 6, had a destabilizing effect on flurbiprofen, which 
is consistent with its role as an inhibitor. The outliers, 19 and 13, both contain hydrogen 
bond accepting groups, suggesting that these two compounds may exert their influence 
on flurbiprofen metabolism through interactions other than pi-stacking. Quantum 
mechanics data are generally accepted as more convincing than classical mechanics-
based energy calculations such as those employed in docking programs 
93
, although, 
because the QM calculations were conducted in a vacuum, rather than in the active site of 
CYP2C9, active site-effector interactions that may in fact override effector-substrate 
interactions are not accounted for and therefore cannot be ruled out. Nevertheless, the 
data here suggest that AutoDock, in which electronic effects are implied in its forcefield, 
may not sufficiently or correctly account for them in its scoring function. The possibility 
also exists that the scoring function lacks a pi-stacking term entirely. 
 In conclusion, AutoDock provided credible effector binding poses, but a sufficient 
correlation between its results and the in vitro/CoMFA-predicted data could not be found. 
Therefore a decision was made to try a different docking program, eHiTS, and repeat the 
effector screening. 
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Figure 4.12. Graphic Representation of  In Vitro Flurbiprofen Metabolism by 
CYP2C9 as a Function of Substrate-Effector Complex Stability. 
The correlation between QM-calculated energetic stability of  flurbiprofen-effector 
complexes and percent in vitro change in flurbiprofen metabolism by CYP2C9 is shown. 
Outliers are colored salmon and are not included in the trendline. 
 
 
 
 
 
 
 
 
 103 
CHAPTER V 
Determination of Effector-Active Site Binding in 
CYP2C9 with eHiTS 
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5.1. Introduction 
 
 
 eHiTS is a docking program similar to AutoDock in that it involves a flexible 
ligand/rigid receptor methodology to conduct virtual HTS within an acceptable range of 
computational expenditure. Both use a grid of discreet interaction energies that form the 
topology of the active site. However, the algorithm employed by eHiTS for docking 
differs from that of AutoDock significantly. As in AutoDock, ligands are divided up into 
fragments separated by rotatable bonds, but eHiTS takes this exercise one step further 
and actually cleaves those bonds, separating the original molecule into rigid fragments 
(functional groups with fixed torsions) and flexible chains (functional groups with 
rotatable torsions). For greater computational economy both the active site topology and 
rigid fragments are more simplistically described by the program as polyhedral shapes, 
with each vertex corresponding to a specific chemical property. eHiTS subsequently 
docks the fragments in the active site individually rather than as a complete molecule. 
This approach enables a wide sampling of computational space inside the binding site 
that would require a much greater computing expenditure if using an intact ligand. 
  During docking all receptor-fragment combinations that do not result in steric 
violations are scored and retained for the next segment in the methodology. Even poorly-
scored pairs are allowed to proceed to the next step due to the fact that their functionality 
in the whole compound may be simply to spatially separate the fragments that are 
contributing to the molecule's binding, rather than forming a binding interaction 
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themselves. All receptor-fragment pairs are archived in a table from which interactions 
may be retrieved if the program docks a compound containing the same rigid fragment as 
one that was previously docked. This tactic becomes especially cost-efficient when 
screening databases, which likely contain several similarly-structured compounds. 
 Next in the methodology is pose-matching, when receptor-fragment pairs are 
oriented spatially to one another such that the distances between them can accommodate 
the flexible chains that connect them. In this step each fragment is represented by a set of 
graph nodes, with each node corresponding to a possible fragment pose. The nodes of 
different fragments are considered to be connectable if there is no steric clash between 
the two poses and the distance between the poses lies within the interval set by the 
flexible connecting chain. Summing the respective scores of the fragments approximates 
the final score of the total molecule closely enough that those node pairs with lower 
summed scores can be discarded and only the most promising pairs retained for further 
processing. Following pose-matching, torsions of the flexible chains are rotated via 
energy-minimization such that they meet the fixed endpoints of the rigid fragments they 
connect at the lowest energy state possible, resulting in a reconstituted molecule. With 
the overall torsional energy factored in, a final score for the whole compound can be 
calculated. 
 The scoring function used by eHiTS is based on a combination of empirical and 
knowledge-based approaches. The empirical approach uses parameters (such as hydrogen 
bonding, van der Waals forces, etc.) weighted such that they can be correlated to 
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experimental data (for example, binding energies). Summing the weighted terms results 
in an approximation of the experimental data. Knowledge-based approaches employ 
statistics gathered from experimental data to develop criteria for preferred interactions. 
These criteria exist in the form of atomic pair potentials and are used to predict binding 
modes rather than binding energies.  
 Surface point energies composed of interaction data calculated via the above two 
approaches are used to determine the scores of ligands at each step of the eHiTS 
algorithm. eHiTS discerns 23 different types of surface points (Table 5.1), which exist at 
each vertex of the ligand and receptor polyhedral representations. The relationship 
between them is based on four variables (Figure 5.1): ligand-receptor interatomic 
distance, the respective angles formed by the atoms involved and a line representing 
interatomic distance, and the dihedral angle formed between the atoms involved. 
Interaction statistics are collected for each type of surface point and each interaction is 
composed of four variables, resulting in a 23 x 23 cell matrix with a four-dimensional 
probability field per cell. From this matrix interaction probabilities are calculated by 
fitting a third degree polynomial equation to the data in each cell using partial least 
squares regression. Converting these probabilities to docking energies is accomplished by 
assigning an energy scaling factor to each matrix cell based on the Boltzmann equation.  
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Table 5.1. The 32 Surface Point Types Recognized by eHiTS. 
 
Surface point definitions used by eHiTS to characterize atomic /electronic interactions 
are listed. 
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Figure 5.1. Four Atomic Relationship Variables Illustrated. 
The relationship between ligand atoms and receptor atoms are determined by four 
variables: their interatomic distance, d; angles ! and "; and torsion angle, #. Lone pairs 
are also considered as “atoms” in this regard, as illustrated in this figure. From 
94
. 
 
 
 
 
 
 
 
 
 
 
 
 109 
The final score includes the aforementioned derived scoring functions and calculated 
energy scaling factors as well as terms for sterics, binding pocket depth, receptor surface 
coverage, ligand conformational strain, ligand intramolecular interactions, and entropy. 
Scores are in units of the log binding affinity constant (pKi). 
 The eHiTS scoring function takes into account the fact that different types of 
receptors require differently weighted parameters for accurate scoring by including 
specific weight sets for 97 different families of receptors based on the residue types that 
comprise the topology of the active site. If the receptor to be used does not belong to any 
of those families then a new set of parameter weights can be developed tailored 
specifically to the receptor in question via enrichment training. The result is a set of 
energy scaling factors (weights) for each parameter unique to the "trained" receptor that 
more accurately describe the energetic strengths of the parameters pertinent to the active 
site.  
 Training can be accomplished either manually by editing the default descriptor 
parameter file, or it can be automated by screening compounds of diverse but known 
biological activity (i.e. a training set). If automated, the process is as follows: First, the 
ligands are docked and the best poses are found. Then, using the best pose of each ligand, 
active site descriptor information is collected in the form of receptor and ligand surface 
point types and statistics on the frequency and geometry of their interactions. The residue 
names and numbers of the heavy atoms to which the surface points belong and the 
distances of the centers of the interacting atoms are also noted. This information is then 
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compared to that in the 97 pre-determined receptor types and then clustered according to 
the frequency with which the descriptor information matches that in a given receptor type 
on a per-residue basis. The relevant weights associated with the descriptor information in 
the pre-determined receptor type is then added to a "weights table" which will be applied 
to the trained receptor the next time a set of compounds is screened through it. Thus the 
resulting trained receptor is, in a way, a conglomerate of other receptors whose 
interaction energies have already been optimized. It must be stated that this clustering 
process is not based on biological activity per se, but rather on the residue types that 
comprise the topology of the active site and binding site similarities between the receptor 
to be trained and those that are already trained. 
 Screening databases through a receptor with eHiTS results in the best scored pose 
of a particular ligand from a user-arbitrated number of clusters. Each cluster is based on 
the ligands' root mean square deviation (RMSd) to each other, which can be changed to 
suit the requirements of the user. eHiTS outputs the top-scoring pose of each compound 
and concatenates the best poses of all compounds in the screened database into one file 
for analysis. An overall score is given for each compound as well as a decomposition of 
individual scoring parameters (H-bonding, hydrophobic interactions, etc.) used to 
compute the overall score, which allows the user to easily determine which interaction 
types are driving the binding pose for a particular ligand. The resulting poses can be 
observed along with pertinent receptor-ligand interactions using a companion visualizing 
program to eHiTS, CheVi. In addition to providing visual information regarding receptor-
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ligand binding, CheVi also provides a decomposition of individual interaction types 
which are scored by the program according to their importance in binding. 
 
5.2. Materials and Methods 
            
5.2.1. Preliminary Structure Preparation 
  A series of dapsone analogs consisting of the first twelve compounds listed in 
Figure 4.1 were built with Sybyl (Tripos, St. Louis, MO) and energy minimized. 
Geometry optimization was performed at the AM1 level with Gaussian 03 (Gaussian, 
Inc., Wallingford, CT). The effector, dapsone, was oriented in the active site of the X-ray 
crystal structure of CYP2C9 
12
 according to the model determined by NMR 
38
 by 
AutoDock3.0. Hexacoordinate heme parameters were obtained from the AMBER 
parameter database maintained by Richard Bryce at the University of Manchester 
(http://pharmacy.man.ac.uk/amber/cof/heme_all_inf.html) 
88
. Flurbiprofen, the substrate, 
had been co-crystallized with the enzyme. A 2 ns molecular dynamics simulation was 
conducted according to the methods in Chapter 4. At the end of the simulation dapsone 
was excised from the active site to create the receptor structure used for docking. Because 
eHiTS automatically takes all possible protonation states of both ligands and receptor into 
account, no preparatory action was taken to protonate/deprotonate ionizable ligands. 
             
5.2.2. Receptor Training   
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 Manual receptor training was undertaken by altering the parameters.cfg file of the 
eHiTS program to weight parameters deemed important for heteroactivation by a 
previously developed predictive CoMFA model [J. S. Aguilar, unpublished]. Parameter 
weight values changed were steric fit scoring weight (from 0.04 in the original 
parameter.cfg file to 1.0 in our altered file), surface contact van der Waals energy (from 
1.0 to 2.0), strongest aromatic Pi stacking interaction energy (from 1.0 to 2.0), and 
strongest hydrogen bond energy (from 1.0 to 2.0). Automated receptor training was also 
conducted using an enrichment training algorithm in which known activators and 
inhibitors are submitted to the docking program. The dapsone analog test set listed in 
Figure 4.1 was divided into activators and non-activators (which included inhibitors) and 
were submitted to eHiTS for the calculation of weighting terms. 
             
5.2.3. Docking Protocol  
 Docking was performed using eHiTS 6.2 at the maximum accuracy setting. The 
docking area boundaries were set at 5 Å from the residues lining the active site of 
CYP2C9. All other settings were left at their default values. The program was run using 
the default parameter weight set, a manually trained receptor, and an enrichment-trained 
receptor. Initially, the 20-compound dapsone analog test set was screened through the 
model, followed by a validation set of the first 60 compounds from the NCI database 95, 
for whom biological activity data was not known. Following this, a second validation set 
consisting of the first 1000 compounds from the NCI database was screened. Both 
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validation sets were seeded with the dapsone analog test set compounds as a control. NCI 
compounds scored higher than dapsone were submitted to in vitro biological activity 
assays to determine the presence and/or degree of heteroactivation of flurbiprofen 
metabolism by CYP2C9. 
        
 5.2.4. Visualization and Analysis of Results  
 Receptor-ligand interactions were visualized and determined using CheVi 
(SimBioSys, Inc., Toronto, Ontario) and PyMol (DeLano Scientific, Palo Alto, CA). H-
bonding was determined visually using a distance cutoff of 4.0 Å between donor and 
acceptor atoms, and pi-interactions were determined by a distance cutoff of 5 Å between 
aromatic ring carbons 74.  
                 
5.2.5. Data Fitting  
 Overall scores and decomposed interaction type scores were fitted to the 
experimental biological activity data using both linear and polynomial regression using 
Microsoft Excel 2004 for Macintosh. 
 
5.3. Results and Discussion 
 Docking a test set of dapsone and 19 dapsone analogs into the active site of 
CYP2C9 using the default eHiTS scoring weights did not yield a significant R2  (overall 
score R2 = 0.01), indicating no correlation between either the overall eHiTS score or the 
individual decomposite interaction scores and the in vitro/CoMFA-predicted increase in 
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flurbiprofen metabolism. The binding mode of dapsone, however, was consistent with 
that found in the AutoDock results in Chapter 4 as well as with the pose found by Wester 
12 in which the sulfone oxygens pointed away from the heme moiety toward the F-G loop 
of the enzyme. In this pose it is able to hydrogen bond with the ammonium side chain of 
Asp-474 by way of its sulfone oxygens (Figure 5.2). The amino group of Ring 1 was also 
able to form H-bonds by interacting with the substrate carboxyl moiety, further 
stabilizing the effector in this position. Another stabilizing interaction present in this pose 
is pi-stacking, which occurs between dapsone and the active site of CYP2C9 as well as 
with flurbiprofen. Ring 1 of dapsone stacked in an offset geometry via 16 pi-pi 
interactions with Ring 1 of flurbiprofen at an average distance of 4.22 Å (Figure 5.3). 
Dapsone also T-stacked via Ring 1 with Phe-476, and Ring 2 formed pi-interactions with 
this residue in an offset geometry. Distances between atoms involved in the rings 
stacking were well within an acceptable cutoff of 5 Å, averaging 4.05 Å from Ring 1 with 
a total number of 9 pi-pi interactions, and an average of 4.36 Å from Ring 2 with a total 
of 3 pi-pi interactions. However, the geometry of the ring overlap between dapsone and 
Phe-476 is not conducive to optimum pi-pi interactions due to the orientation of the 
participating rings; the rings were so severely offset that orbital overlap would be 
minimal (Figure 5.4). The stacking conformation of the dapsone-flurbiprofen pair, 
however, was more favorable due to a closer alignment of the  contributing rings.  
 Though the majority of dapsone analogs docked with their sulfone oxygens 
pointed toward the F-G loop, eight assumed an "alternative" pose, with sulfones pointed 
toward the heme (Figure 5.5). Ring 2 of these effectors (2, 4, 5, 11, 13, 15, 17 and19) 
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Figure 5.2. Hydrogen Bonding of Dapsone Docked Into The Untrained Receptor. 
Hydrogen bonds formed between dapsone and the flurbiprofen-CYP2C9 complex using 
default scoring function weights are illustrated. Flurbiprofen is forest, the heme is 
crimson, dapsone is tangerine, and active site residues are in royal blue. Distances are in 
Ångstroms. 
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Figure 5.3. Pi- Interactions Between Flurbiprofen And Dapsone Docked In The 
Untrained Receptor. 
Pi- interactions between dapsone and the flurbiprofen using default scoring function 
weights are illustrated. Flurbiprofen is forest, the heme is crimson, dapsone is tangerine, 
and active site residues are in royal blue. Black dotted lines indicate pi-interactions. 
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5.4. Pi- Interactions Between Aromatic Active Site Residues Of CYP2C9 And 
Dapsone In The Untrained Receptor. 
Pi- interactions between dapsone and the aromatic active site residues of CYP2C9 using 
default scoring function weights are illustrated. Flurbiprofen is forest, the heme is 
crimson, dapsone is tangerine, and active site residues are in royal blue. Black dotted 
lines indicate pi-interactions. 
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Figure 5.5. Overlay Of Dapsone Analogs Docked In The Alternative Pose In The 
Untrained Receptor. 
Dapsone analog effectors that assumed an alternative pose in the untrained receptor are 
illustrated. Effectors are magenta and are overlaid as lines in the interest of clarity. 
Flurbiprofen is forest, the heme is crimson, dapsone is tangerine, and active site residues 
are in royal blue. 
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stacked closely in an offset "T" geometry with Ring 1 of flurbiprofen. The same effector 
rings were T-stacked with Phe-476. Interestingly, all of the dapsone analogs taking the 
alternative pose were substituted with electron-donating groups in the para position of 
the ring involved in stacking with Phe-476/ flurbiprofen. It is likely that electron donating 
groups increased the electron density of the aromatic ring via resonance effects (-OH, -
NH), or, to a lesser degree, inductive effects (-CH3), resulting in stronger pi-pi 
interactions with other aromatic rings 
96, 97
. Stronger stacking between the effector ring 
systems and aromatic active site residues like Phe-476 may make the favorability of the 
alternative pose energetically competitive with H-bonding of the sulfone oxygens to Asn-
474.  
 Compounds that were para substituted with electron-donating groups that were 
also capable of accepting H-bonds formed electrostatic interactions with the side chain 
ammonium group of Asn-474, further stabilizing them in the alternative position. It 
should be noted that included among the activator compounds that docked in this position 
were the top three activators in vitro: (dapsone,11 and 19), and that the degree of in vitro 
heteroactivation for these three effectors corresponded to the electron-donating capacity 
of the p-substituents. The exception to this is 15, which is a weak inhibitor of flurbiprofen 
metabolism (-5%), may have the potential to be an activator due the fact that carboxylates 
are strong electron donating groups, and thus would greatly increase the electron density 
of the effector aromatic ring. However, this compound is a dianion at physiological pH 
and the formal negative charge clashes with that of the substrate, rendering a close 
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proximity between the two compounds nearly impossible, and canceling out any 
activating qualities the effector may have. Assuming that the remainder of the inhibitors 
docking in the alternative pose are competitive inhibitors and therefore more likely to 
dock in the substrate binding pocket than they are in the "effector" pocket, it would 
appear that pi-stacking plays a very important role in activation of flurbiprofen 
metabolism by CYP2C9. As a corollary, electron-donating p-substituents on the aromatic 
rings involved in stacking with flurbiprofen will increase the strength of the pi-pi 
interaction between substrate and effector, thereby holding flurbiprofen more securely in 
a position conducive to 4'- oxidation. This data suggests that the probability that a given 
compound will induce flurbiprofen metabolism by CYP2C9 can be in part determined by 
the electron-donating capacity of its aromatic ring substituents. 
 Close stacking involving the same rings of dapsone analogs that formed pi-
interactions with flurbiprofen was also observed with Phe-476. The alternative pose 
enabled the effectors to accomplish greater pi-orbital overlap with Phe-476 based on the 
more favorable geometry of the ring pair involved, which allowed a larger number of pi-
interactions between rings with shorter distances between them compared to the ring 
geometry of the dapsone-Phe-476 pair. Effectors that did not assume the alternative pose 
preferred to dock with one of their aromatic rings in this region of dapsone Ring 1 
(Figure 5.6).   
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Figure 5.6. Overlay Of All Dapsone Analogs Docked In The Untrained Receptor. 
Dapsone analog effectors docked in the active site of the untrained receptor are shown. 
Effectors are magenta and are overlaid as lines in the interest of clarity. Flurbiprofen is 
forest, the heme is crimson, dapsone is tangerine, and active site residues are in royal 
blue. 
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 Following this it was decided to manually alter the default weights to reflect the 
importance of the specific descriptors identified by the predictive CoMFA model as most 
relevant to heteroactivation of flurbiprofen metabolism in CYP2C9. Although eHiTS 
does possess a built-in, automated weight-training function, the fact that some knowledge 
of important descriptors was already in-hand made the manual route a better choice to 
start with, as it enables the user to guide the scoring function more directly. As in the 
default weight eHiTS run, the docking results of the manually configured parameter file 
placed dapsone in a conformation consistent with that seen in both the AutoDock results 
and the literature [Wester]. Several pi-interactions were observed in the results between 
dapsone and flurbiprofen (Figure 5.7): Ring 1 of dapsone stacked with both rings of 
flurbiprofen in an offset geometry that involved a total of 31 pi-interactions with an 
average distance of 4.37 Å, and Ring 2 of dapsone T-stacked with Ring 2 of the substrate 
via 15 interactions averaging a distance of 4.26 Å. Pi- stacking between dapsone and 
aromatic active site residues were limited to 9 interactions between Ring 1 and Phe-476, 
resulting in a T-stack geometry and having an average distance of 4.21 Å (Figure 5.8). 
H-bonds formed between the sulfone oxygen of dapsone and the amino side chain of 
Asn-474, as well as between the carboxylate group of the substrate and the amino 
hydrogens of dapsone Ring 1 (Figure 5.9).  
 Compared to the results using default weights, fewer effectors assumed the 
alternative pose, with sulfones pointing toward the heme, but the four that did (dapsone,  
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Figure 5.7. Pi- Interactions Between Flurbiprofen And Dapsone Docked In The 
Manually Trained Receptor. 
Pi- interactions between dapsone and flurbiprofen using manually configured scoring 
function weights are illustrated. Flurbiprofen is forest, the heme is crimson, dapsone is 
tangerine, and active site residues are in royal blue. Black dotted lines indicate pi-
interactions. 
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Figure 5.8. Pi- Interactions Between Aromatic Active Site Residues Of CYP2C9 And 
Dapsone In The Manually Trained Receptor. 
Pi- interactions between dapsone and the aromatic active site residues of CYP2C9 using 
manually configured scoring function weights are illustrated. Flurbiprofen is forest, the 
heme is crimson, dapsone is tangerine, and active site residues are in royal blue. Black 
dotted lines indicate pi-interactions. 
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Figure 5.9. Hydrogen Bonding of Dapsone Docked Into The Manually Trained 
Receptor. 
Hydrogen bonds formed between dapsone and the flurbiprofen-CYP2C9 complex using 
manually configured scoring function weights are illustrated. Flurbiprofen is forest, the 
heme is crimson, dapsone is tangerine, and active site residues are in royal blue. 
Distances are in Ångstroms. 
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11, 15 and 19) were the same para- substituted compounds with electron-donating groups 
that docked in the alternative pose using the default weights. The rings of these effectors 
formed pi-interactions with Phe-476, Phe-114, and Phe-100 in addition to flurbiprofen 
(Figure 5.10). Superimposing the alternatively posed effectors with dapsone revealed a 
common site of ring overlap centered on Ring 1 of dapsone, where the greatest number of 
effector-substrate pi-interactions occurred. It is important to note that the center of 
effector overlap was not situated in a location that allowed for more interaction with 
active site residues, which suggests that interactions with flurbiprofen are a greater 
determinant of effector binding than those with active site residues. Effectors that docked 
with sulfones toward the F-G loop overlapped well with dapsone and were able to stack 
with both rings of flurbiprofen (Figure 5.11). 
 Scoring also improved somewhat, though all generated scores still lacked 
statistical significance; the decomposite interaction scores were slightly more promising 
compared to those obtained using the default weights, with the "Other" category having 
the best correlation of all categories (R
2
 = 0.37, up from 0.27 using default parameters).  
 Automated enrichment training of the receptor was subsequently undertaken to 
assess the ability of the native weight-training function of eHiTS to produce docking 
scores more highly correlative to the in vitro/CoMFA-predicted data. In the results of this 
run dapsone docked in the alternative position (Figure 5.12), with sulfones directed 
toward the heme. In this pose Ring 1 of the effector readily stacked with Phe-100 in an  
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Figure 5.10. Overlay Of Dapsone Analogs Docked In The Alternative Pose In The 
Manually Trained Receptor. 
Dapsone analog effectors that assumed an alternative pose in the manually trained 
receptor are illustrated. Effectors are magenta, flurbiprofen is forest, the heme is crimson, 
dapsone is tangerine, and active site residues are in royal blue. 
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Figure 5.11. Overlay Of All Dapsone Analogs Docked In The Manually Trained 
Receptor. 
Dapsone analog effectors docked in the active site of the manually trained receptor are 
shown. Effectors are magenta and are overlaid as lines in the interest of clarity. 
Flurbiprofen is forest, the heme is crimson, dapsone is tangerine, and active site residues 
are in royal blue. 
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Figure 5.12. Pi- Interactions Between Aromatic Active Site Residues Of CYP2C9 
And Dapsone In The Enrichment Trained Receptor. 
Pi- interactions between dapsone and the aromatic active site residues of CYP2C9 using 
enrichment-trained scoring function weights are illustrated. Flurbiprofen is forest, the 
heme is crimson, dapsone is tangerine, and active site residues are in royal blue. Black 
dotted lines indicate pi-interactions. 
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offset geometry with an average distance of 4.41 Å via 14 interactions. Other pi-
interactions with Phe-114 (average distance 4.01 Å with 8 interactions) were also 
observed via Ring 1 of dapsone, as well as with Phe-476 (average distance 4.55 Å with 
11 interactions), though poor pi orbital overlap with these residues meant that interactions 
with them were weak. Pi-interactions with flurbiprofen were still present between 
dapsone Ring 2 and both rings of flurbiprofen (Figure 5.13) in a geometry resembling 
that seen in benzene trimers (Figure 5.14). Considering the large number of aromatic 
rings present in the active site in addition to aromatic active site residues when dapsone 
or its analogs are bound simultaneously with flurbiprofen, higher order pi-stacking is a 
very conceivable possibility. No H-bonds were formed between dapsone and flurbiprofen 
or Asn-474. 
 As in the previous two eHiTS runs, dapsone analogs that assumed an alternative 
pose (10 and 16) were superimposable with dapsone, with stacking occurring between the 
effectors and Phe-100 in an offset geometry as well as both rings of flurbiprofen (Figure 
5.15). Neither effector contained electron-donating groups that would increase electron 
density in their aromatic ring systems. Effector compounds that docked with their sulfone 
groups directed at the F-G loop overlapped dapsone Ring 2-- the same ring involved in 
the trimeric pi-stacking with flurbiprofen (Figure 5.16). 
 Only 5 of the 9 total activators in the training set were used in the enrichment 
training, due to the fact that the activity values of the other 4 were CoMFA-predicted. 
Because the correlation coefficient of  the CoMFA model was high (0.80), a predictive 
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model can be built using manual methods such as parameter file editing without the need 
to differentiate the in vitro activity values from the CoMFA-generated values. This is 
especially true when the parameters being altered are descriptors identified by the 
CoMFA model as important to heteroactivation of flurbiprofen metabolism in CYP2C9. 
However, the enrichment training algorithm is complex enough that it may identify other 
descriptors that the CoMFA model missed. It was decided that, in the interest of 
preventing biasing the enrichment training with CoMFA data, the receptor should be 
trained using in vitro values only.  
 The overall scores that resulted from using the enrichment-trained receptor were 
more correlative to the in vitro/CoMFA-predicted data compared to both the manually 
configured run and the default parameter run. Again, the "Other" category possessing the 
best correlation coefficient (R
2
 = 0.44). Despite the improvement in scores, there still 
existed no statistical correlation with the in vitro/CoMFA-predicted data. It was 
postulated that the low correlation could be due to the possibility that some compounds in 
the test set may elicit their effect on flurbiprofen metabolism by means of different 
mechanisms, for example inhibitors may be competitive inhibitors and prefer to dock in 
the substrate binding site, where eHiTS cannot dock them due to the rigidity of the 
receptor structure (in which flurbiprofen is present).  
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Figure 5.13. Pi- Interactions Between Flurbiprofen And Dapsone Docked In The 
Enrichment Trained Receptor. 
Pi- interactions between dapsone and flurbiprofen using enrichment trained scoring 
function weights are illustrated. Flurbiprofen is forest, the heme is crimson, dapsone is 
tangerine, and active site residues are in royal blue. Black dotted lines indicate pi-
interactions. 
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Figure 5.14. Optimized Orientation Of A Clustered Benzene Trimer. 
Optimized orientation of a clustered benzene trimer is shown. From McGaughey et al 
98
. 
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Figure 5.15. Overlay Of Dapsone Analogs Docked In The Alternative Pose In The 
Enrichment Trained Receptor. 
Dapsone analog effectors that assumed an alternative pose in the enrichment trained 
receptor are illustrated. Effectors are magenta, flurbiprofen is forest, the heme is crimson, 
dapsone is tangerine, and active site residues are in royal blue. 
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Figure 5.16. Overlay Of All Dapsone Analogs Docked In The Enrichment Trained 
Receptor. 
Dapsone analog effectors docked in the active site of the enrichment trained receptor are 
shown. Effectors are magenta and are overlaid as lines in the interest of clarity. 
Flurbiprofen is forest, the heme is crimson, dapsone is tangerine, and active site residues 
are in royal blue. 
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 It stood to reason that calculating the R
2
 of activators separately from non-
activators (inhibitors and do-nothings) may improve the correlation since they are more 
likely to activate metabolism using similar mechanisms. Using this approach the R
2
 of the 
"Other" category for activators in the test set dropped to 0.30. Thus far the regression 
analyses had been linear in nature. Applying a second-order polynomial equation to the 
data for activators lowered the R
2
 of the "Other" category to 0.30. Interestingly, applying 
the same polynomial function to the overall score raised that R
2
 value to 0.60, which is 
statistically significant (Figure 5.17).  
 The "Pi-stacking" category did not benefit from the polynomial function (R
2
 = 
0.23), which is at odds with the binding modes of the docked effectors. It is possible that 
the scoring function used to define the pi-stacking term may be insufficient, but it may be 
compensated for by other surface point descriptors used to calculate other terms that also 
contribute to the overall score. The likelihood is good that this is an example of an all-
too-common phenomenon in which the native scoring function of a docking program 
possesses sophistication enough to determine the correct binding pose, but not enough to 
provide a correlative docking energy.  
 The most relevant correlation is that of the overall score due to the fact that eHiTS 
uses this score, and not the individual decomposite scores, to rank docked compounds  
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Figure 5.17. eHiTS Activator Scores And Correlation Coefficients After Enrichment Training Of The Receptor. 
eHiTS activator scores and correlation coefficients obtained from the enrichment trained receptor are illustrated. 
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from a screened database; with a high correlation coefficient, eHiTS is more likely to 
rank as-yet unknown heteroactivators higher in the output results, making discovery of a 
new activating compound more likely in turn. 
 Any data can be fitted using the right function, however, and a good R
2
 does not 
by default constitute a true relationship between the in vitro/CoMFA-predicted data and 
calculated scores. Rather, the equation must relate to a physical model. In this case the 
parabolic data suggests that as the substrate-effector interactions become stronger 
flurbiprofen turnover increases, until a point is reached at which the increasing strength 
of the interactions begins to reduce the rate of metabolism. At the point at which 
metabolism begins to increase, substrate-effector interactions would become dominant 
over effector-enzyme and substrate-enzyme interactions. This is reflected in all three sets 
of eHiTS docking results, in which effector compounds in general prefer to pi-stack with 
the substrate rather than with active site residues. However, beyond a certain point those 
interactions become strong enough that they actually begin to slow the turnover rate. The 
reason for the reduction in metabolism could be due to pi-interactions between 
flurbiprofen and the effector that may increase the electron density of the metabolized 
ring such that the 4'-hydrogen of the substrate becomes less acidic, and thus less inclined 
to react with the heme. Another possibility is supported by the MD simulation discussed 
in Chapter III, in which dapsone was shown to draw the substrate away from the heme 
when the distance between their rings was very close, but appeared to stabilize the 
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substrate in a position closer to the heme when the dapsone-flurbiprofen ring distances 
were somewhat greater. 
It should be noted that when dapsone and flurbiprofen are each docked individually into 
the empty active site of CYP2C9, their resulting eHiTS scores (-3.94 pKi and -5.79 pKi, 
respectively) are both less negative than the eHiTS score for dapsone docked into the 
active site in the presence of flurbiprofen (-7.90 pKi). Also less negative is the score 
generated by docking flurbiprofen into a dapsone-CYP2C9 complex (-6.03 pKi). This 
supports the QM/MM data described in Chapter IV, and suggests several things. First, 
that dapsone energetically favors binding as an effector rather than binding as a substrate 
in the presence of flurbiprofen (this has been demonstrated in previous literature 
42
; 
second, that  this preference is due to the presence of flurbiprofen and likely results from 
direct interactions with flurbiprofen; lastly, because the docking run was conducted inside 
the active site of CYP2C9 and not in a vacuum like the QM/MM calculations, the 
docking results indicate that the dapsone-flurbiprofen complex was not lower in energy 
than the compounds comprising it individually due to a lack of possibly important 
protein-effector interactions. Rather, active site residue-effector interactions do not 
outweigh substrate-effector interactions as factors that stabilize the dapsone-flurbiprofen 
complex in the active site of CYP2C9.  
 The fact that the score for dapsone docked in the presence of flurbiprofen was 
also lower than the score for flurbiprofen docked alone in the active site is a strong 
indicator that it is more energetically favorable for flurbiprofen to assume a metabolite-
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producing binding pose in the presence of dapsone than it is in the absence of the 
effector. This points to dapsone-flurbiprofen interactions as being important factors in 
heteroactivation in this biological system, and suggests that dapsone activates 
flurbiprofen metabolism directly, as opposed to the hypothesis that dapsone may bring 
about heteroactivation indirectly by causing the substrate to interact with different active 
site residues. 
 
5.4. Conclusion 
 Dapsone assumed both a "sulfone oxygens up" and an alternative, "sulfone 
oxygens down" pose. It is likely that dapsone has the ability to dock in either pose in the 
active site of CYP2C9. In addition to the added stabilizing effects of H-bonding with 
flurbiprofen carboxy oxygens, which was only observed in the non-alternative confomer, 
the "sulfones up" conformation may be more common due to a shorter average distance 
between stacking rings with superior stacking geometry as seen in the pi-interactions 
between dapsone and flurbiprofen. Interestingly, in all eHiTS runs pi-stacking between 
the dapsone and flurbiprofen was either as strong as or superior to that between dapsone 
and active site residues based on ring geometry and distance, leading to the conclusion 
that direct interaction with the substrate is at least in part responsible for dapsone 
activation of flurbiprofen metabolism by CYP2C9.  
 In all runs, effectors that assumed the alternative pose overlapped more closely 
with each other such that one of their aromatic rings was in position to better form pi-
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interactions with Ring 1 of flurbiprofen. Effectors that docked with sulfones directed 
toward the F-G loop did not superimpose quite as well; they tended to deviate just far 
enough from the alternative confomer rings to be able to stack with Ring 2 of 
flurbiprofen in addition to or instead of Ring 1, depending on the effector. Higher-order 
stacking interactions such as trimers between the substrate and effectors could also be 
formed, as observed in the enrichment-trained run. All effectors engaged in stacking 
interactions with the substrate. Also, effector rings involved in those interactions 
regardless of the docked conformation were nearly always p-substituted with an electron-
donating group, which, depending on the group, would add electron density to the 
attached ring and thus enable it to form stronger pi-interactions. 
 Substituent effects appeared to play an important role in determining the degree of 
heteroactivation elicited by a given effector compound, with increasing electron-donating 
ability of a substituent corresponding to greater in vitro heteroactivation. Alteration in 
electron densities of rings involved in activator-substrate pi-stacking resulted in a 
parabolic relationship between the in vitro/CoMFA-predicted data and overall scores 
calculated by eHiTS after enrichment training of the receptor; as heteroactivator-substrate 
pi-stacking interactions became stronger (due to substituent effects on the participating 
ring of the effector) flurbiprofen could be held more securely in a position conducive to 
4'-oxidation. At a certain point, depending on the activator, the pi-interactions became 
strong enough that they altered the electron density of the substrate ring(s) such that the 
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4'- hydrogen becomes less inclined to react with the heme, resulting in a parabola when 
the data is fitted to a line.
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CHAPTER VI 
Development of a Statistical Model for Effectors of 
Flurbiprofen Metabolism in CYP2C9 
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6.1. Introduction 
 
 The correlation coefficient of determination calculated in Chapters IV and V, R2, 
is a measure of the internal validity of a statistical model. High R2 values indicate that the 
training set data correlates well with the experimental values, and therefore indicate that 
the model is deemed accurate in predicting those compounds used in its development. 
However, R2 does not provide a measure of the ability of the model to correctly predict 
activities of compounds not present in the test set. A cross-validated correlation 
coefficient, q2, provides a means to assess the overall predictive power of the model, i.e., 
how well the model can predict the biological activities of external compounds. There are 
several methods employed in cross-validating a model, the most common being the 
leave-x-out algorithm, and activity permutation.  
 The leave-x-out method ascertains whether or not the model is being driven by x 
number of compounds. The “x” in this case is not a variable in an equation per se, but 
rather an arbitrary number of compounds in the training set. The rationale behind this 
method is that a robust model should be able to be “rebuilt” sans x number of compounds 
from its original training set and still correctly predict the activities of those compounds 
that were left out of the rebuilt version. The validation is therefore carried out by building 
additional statistical models using the original training set of the model being validated, 
but in each test model one or more compounds in the training set is left out. Fitting each 
rebuilt model will result in a correlation equation. The activity value predicted by the 
original model for the compound left out of the rebuilt model is then substituted for x in 
the correlation equation obtained from fitting the rebuilt model, and is used to solve for 
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the dependent variable y. The result is ! , which ideally will be numerically close to y. 
This process is repeated until a model lacking at least one of every compound in the 
training set for the original model has been constructed and its data fitted. !  values 
calculated for the models can be correlated to the in vitro/CoMFA-predicted data by 
calculating a cross-validated correlation coefficient, q2, using equation 6.1: 
 
 q2 = 1- [!(y-!)2/!y2]         (6.1.) 
 
where y is the observed biological activity and !  is the cross-validated calculated 
activity. The q2 value can range anywhere from -1 to 1, with values closer to 1 indicating 
a higher correlation between the calculated and observed activities and negative values 
indicating no correlation whatsoever-- literally, a correlation worse than "no model at 
all". 
 Generally speaking, the greater number of compounds left out of the cross-
validation test models, the more reliable the test. However, the leave-one-out algorithm 
(LOO) has shown itself to suffice when the original training set consists of roughly 30 
compounds or less, and has been successfully employed in the development and 
verification of several pharmacophore models 
47, 49, 54, 71, 73
. A large training set requires a 
more stringent algorithm (such as leave-20%-out) since more compounds in the set 
means more "noise" (independent variables that contribute very little to the biological 
activity, but in large numbers can appear deceptively strong). With enough "noise", the q2 
is more likely to approach 1.0 but may in fact be statistically irrelevant. Leaving out a 
greater number of compounds increases the "signal-to-noise" ratio, thus identifying the 
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factors most responsible for the biological activity and ensuring that it is they, not the 
"noise", that are actually driving the model. 
 Another method of cross-validation is by permuting the biological activities of the 
training set compounds. Permutation is defined as the repeated randomization of the 
activities of the training set compounds such that each value is no longer assigned to the 
original molecule. A model, deemed the "null hypothesis" due to the fact that the data is 
presumed to have no relationship to the observed activity, is then built using the 
permuted values. The correlation coefficient determined from this model should be 
statistically insignificant; if that is in fact not the case, then the actual, non-permuted, 
model may be due more in part to chance. The difference between the estimated 
biological activity generated by the model and the experimental activity, the total energy 
cost, is also calculated for both the permuted and the actual models. The greater the 
difference in total energy costs of the null hypothesis and the actual model, the smaller 
the likelihood that chance is responsible for correlation of the activities predicted by the 
actual model to those observed. A model that yields a poor q2 can be refined and retested 
until a statistically significant q2 can be obtained from it. Once the model is deemed 
sound, an external database of compounds with unknown biological activities can be 
screened, and those identified by the model as probable effectors can be subsequently 
evaluated in vitro to assess their actual biological activity. 
 
6.2. Materials and Methods 
 
6.2.1. Cross-Validation of the Model  
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 The LOO algorithm was used to cross-validate the model. Eleven statistical 
models were generated by eHiTS using the enrichment-trained 2C9-flurbiprofen complex 
receptor, and test set activator compounds only; in each model one activator was not 
included in model development. The data was fitted using polynomial regression in 
Excel, and the resulting regression coefficients were applied to the overall score of the 
excluded compound as calculated by eHiTS. From this equation ! was solved. This 
process was repeated for every activator in the training set. All ! were summed and a q2 
was calculated using equation 6.1, above. It should be noted that, although the original 
model was generated using only the in vitro values, the cross-validation was performed 
using all 19 dapsone analogs. 
  
6.2.2. NCI Database Screening  
 The National Cancer Institute (NCI) database of drug-like compounds was chosen 
as the external data set to be screened due to the fact that the compounds that comprised 
it were known to possess pharmacological properties, though their biological activity 
regarding flurbiprofen metabolism by CYP2C9 was unknown. In addition, many 
compounds could be obtained from commercial sources should they require in vitro 
metabolism studies. The first 858 compounds were arbitrarily excised from the database 
and were subjected to a molecular weight filter using the Concord module of Sybyl7.0 
(Tripos, Inc. St. Louis, MO) that excluded compounds below 120 amu and those above 
350 amu. Metallic or isotopic compounds were also excluded. Because dapsone analogs 
require aromaticity to activate flurbiprofen turnover, NCI compounds were required to 
possess at least one aromatic ring. Potential chirality of the compounds was included. The 
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resulting filtered database was converted to 3D coordinates and then screened by eHiTS 
using the enrichment-trained 2C9-flurbiprofen complex receptor with the same protocol 
described in Chapter V. Results of the screening were visualized using PyMol (DeLano 
Scientific, Palo Alto, CA) and CheVi. 
 
6.3. Results and Discussion 
 The results of the LOO cross-validation can be viewed in Table 6.1. Substituting 
the value obtained by solving the fitted equation for each compound in the training set 
one-by-one yielded high correlation coefficients for every compound, which indicates 
that no single compound in the training set was driving the model and that the model was 
therefore robust. The q
2
 value calculated from these coefficients was statistically 
significant at 0.6966, suggesting that the model possessed predictive power sufficient to 
reliably screen external databases for unknown heteroactivators. To this end, a small 
segment of the NCI database consisting of the first 60 compounds was screened through 
the model. As a control, the database was seeded with known dapsone analog activators 
from the test set used to develop the model. eHiTS ranked 6 out of 9 total 
heteroactivating dapsone analogs (67%) in the top 16 docked compounds and identified 
several NCI compounds as activators (Figure 6.1). The new compounds identified 
possessed structural similarities to dapsone (aromatic rings separated by one or more 
rotatable bonds), and took on a similar docked geometry to dapsone as well (Figure 6.2). 
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Table 6.1. Cross-Validation Results 
 
 
Compound Left Out And Solved For Regression Coefficients ! y R
2 
 A B C    
Diphenylsulfoxide (14) -2.8317 -94.985 -732.80 21.568 5.03 0.5660 
Diphenylsulfone (10) -3.1442 -106.31 -832.03 58.411 39.98 0.6299 
Diparatolylsulfone (11) -3.0342 -102.53 -801.66 58.618 50.57 0.5888 
Dapsone (12) -2.7887 -94.089 -733.81 48.388 64 0.5711 
Dacetamidophenylsulfoxide (14) -2.5536 -87.450 -687.64 28.529 5.03 0.5918 
Dibenzothiophenesulfone (16) -3.5477 -121.46 -975.36 -20.336 17.82 0.6737 
Hydroxyphenylmethoxyphenylsulfone (17) -3.0033 -100.68 -778.18 36.725 17.92 0.6147 
Diacetamidophenylsulfone (18) -3.0808 -103.73 -809.50 2.111 8 0.5532 
Dihydroxyphenylsulfone (19) -2.3590 -79.502 -617.51 45.058 95 0.7047 
Methoxyphenylsulfone (20) -3.1611 -106.78 -835.21 61.186 44.84 0.6178 
 
Leave-one-out cross-validation calculation results are shown. The regression coefficients were calculated for a second-order    
polynomial function, where ! = Ax2 + Bx + C.
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Figure 6.1. NCI Compounds in the Top 20 Identified by eHiTS As Activators of 
Flurbiprofen Metabolism by CYP2C9. 
NCI compounds in the top 20 compounds identified by eHiTS as heteroactivators of 
flurbiprofen 4’-hydroxylation by CYP2C9 are illustrated. 
21 22         23   24 
    29               30     31               32 
     33               34 
      25             26      27                   28 
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Figure 6.2. NCI Compounds Identified by eHiTS as Activators Docked in the Active 
Site of CYP2C9 in the Presence of Flurbiprofen. 
NCI compounds identified as activators of flurbiprofen metabolism are shown overlaid 
with dapsone for comparison. The NCI compounds are in magenta as lines, dapsone is 
tangerine, flurbiprofen is forest, active site residues are marine, and the heme is crimson. 
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 eHiTS ranked several NCI compounds with multiple rings (compounds 21, 22, 
23, 24, 25 and 26) higher than any of the dapsone analog activators. These compounds 
were able to interact more closely with active site residues than the dapsone analogs, and 
all but one (26) formed pi-stacking interactions with flurbiprofen simultaneously. This 
may in part be due to the greater number of rotatable bonds separating the aromatic rings 
involved in pi-stacking, which not only allows the effector to span the distance between 
the active site residues and the substrate, but also to rotate its rings to maximize orbital 
overlap. These multi-ring effectors tended to position themselves such that they were able 
to form interactions with both rings of flurbiprofen in an offset geometry, but if the 
structure of the effector prevented this type of pose, the effector would stack with Ring 1 
of flurbiprofen rather than Ring 2, possibly because this arrangement enabled the effector 
to favorably interact with active site phenylalanine residues simultaneously. Interestingly, 
three of these six high-ranking multi-ring compounds (21, 23, and 26) formed a 
pinwheel-like trimer between one effector ring, Phe-100, and Phe-114 (Figure 6.3) and 
(Figure 6.4). The other three (22, 24, and 25) formed dimers with Phe-476. The ability of 
these effectors to form complex interactions with aromatic residues may stabilize them in 
position to better pi-stack with the substrate, which may account for their higher ranking 
as effectors by the docking program. 
In vitro testing of the top 20 docked compounds from the NCI database seeded 
with dapsone analogs confirmed 4 compounds from the as activators of flurbiprofen 
metabolism by CYP2C9 (Table 6.2). Three of these compounds (24, 25, and 28) 
possessed activities ranging from a 4.26% increase in 4’-hydroxyflurbiprofen production  
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Figure 6.3. Pi-Interactions Formed by Compound 21 Docked in the Active Site of 
CYP2C9 in the Presence of Flurbiprofen. 
Compound 21 is shown docked in the presence of flurbiprofen in the active site of 
CYP2C9. Dapsone is overlaid in comparison. 21 is magenta, dapsone is tangerine, 
flurbiprofen is forest, active site residues are marine, and the heme is crimson. Pi-
interactions are denoted by dotted lines. 
 
 
 154 
 
 
Figure 6.4. Docked NCI Compounds Identified by eHiTS as Activators of 
Flurbiprofen Metabolism by CYP2C9 Possessing Three Or More Rings. 
Docked NCI compounds identified by eHiTS as heteroactivators of flurbiprofen 
metabolism by CYP2C9 possessing three or more rings are illustrated. Dapsone is 
overlaid for comparison. The NCI compounds are magenta, dapsone is tangerine, active 
site residues are marine, flurbiprofen is forest, and the heme is crimson. 
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Table 6.2. Activators of Flurbiprofen Metabolism by CYP2C9 Identified in the 
Seeded NCI Database by eHiTS. 
 
Rank Compound 
Number 
Name % change in 
flurbiprofen 
metabolism 
at 5 !M 
effector 
concentration 
% change in 
flurbiprofen 
metabolism 
at 10 !M 
effector 
concentration 
4 24 N-(diphenyl methylene) aniline 4.26 -7.95 
5 25 !-"-diphenylhydrocinnamonitrile 5.23 -2.61 
8 28 2,2#-dithiobis(benzothiazole) 7.82 -20.55 
10 17 4-[(4-methoxyphenyl)sulfonyl] phenol 115.20 140.14 
27 12 Dapsone 16.56 79.52 
54 35 3-methyl-1-phenyl-2pyrazolin-5-one -16.78 -30.50 
Positive numbers indicate activation; negative numbers indicate inhibition. 
Flurbiprofen concentration held constant at 10 $M for all tests. 
 
New activators of flurbiprofen 4’-hydroxylation by CYP2C9 identified by screening the 
seeded NCI database using eHiTS and their in vitro activities are listed. 
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to 7.82% at a low effector concentration of  5 µM (flurbiprofen concentration was 10 
µM). For perspective, at this low concentration dapsone activated flurbiprofen 
metabolism by 16.56%, which marks the newly identified effectors as moderate 
activators. However, raising the effector concentration to 50 µM turns these same 3 
compounds into inhibitors of flurbiprofen metabolism. It is possible that these effectors 
have an affinities for the substrate binding site similar to that of flurbiprofen, but also 
have enough of an affinity for the effector binding site to serve as activators at 
concentrations lower than the concentration of substrate, when flurbiprofen is more likely 
to occupy the substrate binding site due to being present in solution in greater numbers 
compared to the effectors. At high effector concentrations the effector compounds 
outnumber the substrate in solution, increasing the chances that an effector will occupy 
the substrate binding site before flurbiprofen can, and thereby causing competitive 
inhibition. 
 The fourth activator compound identified by the model was one dapsone analog 
that was not part of the set of compounds used to develop the model due to its lack of in 
vitro activity values was scored by eHiTS as an activator stronger than dapsone. This 
compound, 17, was ranked 10
th
 whereas dapsone lagged behind at 27
th
 place. The 
CoMFA model predicted 17 would activate flurbiprofen metabolism by CYP2C9 by 
about 18%, as seen in Table 4.1. However, in vitro testing revealed a much higher 
activity than the CoMFA model had predicted at 115.2%. This percent turnover increase 
was obtained using concentrations of 5 µM activator and 10 µM flurbiprofen. At effector 
concentrations of 50 µM the rate of metabolism increases to 140.14%. Compared to the 
other three new activators, this compound may have a greater affinity for the effector 
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binding site and less affinity for the substrate binding site, or it may form stronger 
interactions with flurbiprofen in the active site that stabilize it in the effector binding 
pocket, or, most likely, a combination of these two mechanisms.  
 It is important to note that the model not only identified a compound not used in 
its development as an activator of flurbiprofen metabolism by CYP2C9, but also 
correctly ranked its activity above that of dapsone (which the CoMFA model that 
predicted its original activity value failed to accomplish, even with a correlation 
coefficient of 0.80). The model also correctly ranked a strong unknown inhibitor (35) of 
flurbiprofen metabolism toward the bottom of the list of  60 compounds at 54 (Figure 
6.5) The compound inhibited substrate turnover by -16.78% at 5 µM and -30.50% at 10 
µM.  
 The discovery of these four compounds indicated that the model is able to 
successfully identify potential effectors whose in vitro activity is unknown. With the 
establishment that the model possesses significant predictive power as determined by 
cross-validation and has practical application as demonstrated by the seeded NCI 
database screen, it is very possible that other, possibly stronger, effectors would be 
discovered by sampling larger portions of the database (only 60 of the total 740 filtered 
compounds were screened); a larger sampling pool increases the chances that the model 
would flag effectors in addition to the four already identified.  
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Figure 6.5. Chemical Structure of 3-methyl-1-phenyl-2pyrazolin-5-one. 
The chemical structure of 3-methyl-1-phenyl-2pyrazolin-5-one (compound 35) is shown. 
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CHAPTER VII 
Summary and Conclusions 
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 The modeling studies conducted and explained in this work have brought about 
greater understanding of the mechanisms responsible for dapsone-mediated activation of 
flurbiprofen metabolism by CYP2C9. It is especially worth noting that effector-substrate 
interactions, which had not been given much attention in previous literature, were shown 
to be of prime importance in effecting heteroactivation. Armed with this information, a 
statistical model capable of high-throughput screening of large databases has been 
developed, making the prediction of the likelihood of a given compound to possess 
activator qualities now possible for this biological system. 
Docking studies using both AutoDock and eHiTS and molecular dynamics simulations 
revealed that both H-bonding and pi-stacking played important roles in the mechanism of 
heteroactivation, with Asn-474 and Ser-209 H-bonding to dapsone, and dapsone (as well 
as dapsone analogs) pi-stacking in various geometries with flurbiprofen and active site 
residues, particularly Phe-476, Phe-114, and Phe-100. Effectors typically formed higher-
order stacking conformations involving the substrate and active site residues. MD 
simulations demonstrated that dapsone, when inside the active site of CYP2C9 in the 
presence of flurbiprofen, moved the 4’-H of the substrate closer to the heme iron by about 
1 Å, which has been shown to occur experimentally via previous NMR studies 100. At 
times this distance reached values as low as 3.27 Å. Interestingly, the simulations also 
revealed that the 4’-H-Fe distance actually increased when pi-stacking rings of dapsone 
and flurbiprofen came within an average of about 4 Å of each other. As the substrate-
effector distance widened to an average of 6.12 Å  (it fluctuated between about 4 and 8.5 
Å) flurbiprofen approached the heme more readily. During the time that dapsone was 
interacting more weakly with flurbiprofen, it was interacting more strongly with Phe-476. 
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This active site residue often formed trimer stacking orientations with the substrate as 
well as with dapsone. There existed also a period of time during the simulation in which 
dapsone closely associated with both Phe-476 and flurbiprofen, pulling the substrate 
away from the heme in the process to the point where metabolism was unlikely to occur. 
These states likely exist in equilibrium, with the weaker dapsone-flurbiprofen interactive 
state predominating.  
 This data, which shows stronger effector-substrate interactions leading to a less-
metabolite-producing scenario and weaker ones leading to a more productive scenario, is 
corroborated by the statistical model developed by eHiTS, which yielded a significant 
parabolic correlation between the interaction-based score it calculates for each effector 
and in vitro effector activity (R
2
 = 0.60). The parabola suggests that the effector can stack 
with flurbiprofen with increasing strength up to a certain interaction energy with the 
effect that the substrate is increasingly better-stabilized in a position closer to the heme 
where it is readily oxidized. When the interaction energy between the two compounds 
exceeds a certain point, the effector is able to pull the substrate away from the heme, and 
it is less likely to be metabolized. The heteroactivator potency appeared to be related to 
the electron-donating capacity of functional groups attached para to the 
sulfone/sulfide/sulfoxide group of the effector rings. In general, the stronger the electron 
donating group, the greater electron-density of the effector ring, the stronger the 
interaction between that ring and the aromatic rings of flurbiprofen and active site 
phenylalanines.  
 The eHiTS scores also indicated that interactions between the substrate and the 
effector itself, not active site residues, are primarily responsible for heteroactivation of 
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flurbiprofen metabolism. The score generated from the docking run in which flurbiprofen 
was docked into a dapsone-CYP2C9 complex was superior to the scores of both the  
dapsone docked into the flp-CYP2C9 complex run and the run in which flurbiprofen was 
docked into CYP2C9 alone. The data suggests that dapsone plays a direct role in 
stabilizing flurbiprofen in a productive position in the active site. In addition, quantum 
mechanics studies of docked conformations of seven effector-flurbiprofen  complexes 
revealed that in the case of all activators but two the complexes were more stable (i.e. had 
lower energies) than either flurbiprofen alone  or the effector alone. 
 The  statistical model developed using the automated training function in eHiTS 
not only yielded a significant cross-validated correlation coefficient of  0.70, but, upon 
screening 60 drug-like compounds from the NCI database, was also able to successfully 
predict four new activators of flurbiprofen 4’-hydroxylation by CYP2C9. One of these 
was shown in vitro to exceed the level of heteroactivity of dapsone, increasing 
flurbiprofen  turnover by as much as 140% . The model also correctly ranked a strong 
unknown inhibitor (35) of flurbiprofen metabolism at 54, near the bottom of the list of  a 
total of 60 screened compounds. The discovery of the activities of these five compounds 
indicated that the model is able to successfully identify potential effectors whose in vitro 
activity is unknown. With the establishment that the model possesses significant 
predictive power as determined by cross-validation, and has practical application as 
demonstrated by the seeded NCI database screen, it is very possible that other, possibly 
stronger, effectors would be discovered by sampling larger portions of the database (only 
60 of the total 740 filtered compounds were screened); a larger sampling pool increases 
the chances that the model would flag effectors in addition to the four already identified.  
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 Though exhibition of atypical kinetics in an enzyme is substrate-specific, the 
effector-substrate interactions discovered here may also apply to other biological 
systems, and the methodology used in developing the predictive statistical model could 
likely also be used for other systems with success. Exploration of such interactions in 
these systems would be worth pursuing in the future,  particularly those involving drugs 
with narrow therapeutic indices such as warfarin. For the reasons given above, this work 
has increased the depth of knowledge with which drug-drug interactions stemming from 
atypical enzyme kinetics can be prevented. 
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